Method for inactivating genes of porcine endogenous retrovirus and composition thereof

A CRISPR/Cas system combined with cytidine deaminase introduces stop codons in PERV genes to efficiently inactivate multiple copies, enhancing the safety of pig organs for transplantation by reducing PERV expression and cell death.

KR103042973B1Active Publication Date: 2026-11-06TOOLGEN INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
KR1020237000584
Authority / Receiving Office
KR · KR
Patent Type
Patents
Current Assignee / Owner
Priority Date
2021-10-25
Filing Date
2022-09-21
Publication Date
2026-11-06
Estimated Expiration
2042-09-21

AI Technical Summary

Technical Problem

Existing CRISPR-Cas systems face challenges in efficiently editing multiple copies of porcine endogenous retrovirus (PERV) genes without causing genome rearrangement and cytotoxicity, which poses a barrier to using pig organs for organ transplantation due to the risk of PERV transmission to humans.

Method used

A method using a CRISPR/Cas system combined with a base modification enzyme, such as cytidine deaminase, to introduce stop codons in the PERV genes, specifically targeting the gag, pol, and env genes, thereby reducing PERV expression by up to 50% and preventing transmission.

Benefits of technology

The method effectively inactivates multiple copies of PERV genes in pig cells, ensuring their safety for organ transplantation by significantly reducing PERV expression and preventing cell death, thus addressing the transmission risk.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure R1020237000584_ABST
    Figure R1020237000584_ABST
Patent Text Reader

Abstract

The present application relates to a composition capable of artificially manipulating PERV genomes that exist as multiple copies within the genome of pig cells, and a method for inactivating PERV using the same.
Need to check novelty before this filing date? Find Prior Art

Description

Technology Field

[0001] The present application relates to the artificial manipulation or modification of a target gene existing in multiple copies. More specifically, it relates to a composition capable of artificially manipulating a PERV genome existing in multiple copies within the genome of pig cells and a method for inactivating PERV using the same. Background Technology

[0002] The CRISPR-Cas system consists of a guide RNA (gRNA) having a sequence complementary to the target gene or nucleic acid and a CRISPR enzyme, which is a nuclease capable of cleaving the target gene or nucleic acid; the gRNA and the CRISPR enzyme form a CRISPR complex, and the target gene or nucleic acid is cleaved or modified by the formed CRISPR complex.

[0003] Generally, genes edited by the CRISPR-Cas system are usually one or two copies, so simultaneous genome editing does not cause major problems. However, when there are multiple copies of the target gene, that is, when multiple copies of the gene are targeted, gene editing using the CRISPR-Cas system can cause serious problems such as genome rearrangement and loss of some nucleic acid fragments through the simultaneous nucleic acid cutting and repair processes, which can lead to results such as cytotoxicity and cell death.

[0004] These problems are also recognized in the field of organ transplantation. The shortage of organs is a major barrier to the treatment of organ failure. Although pig organs are considered a promising solution to the organ shortage, the use of pig organs still faces unresolved issues regarding the transmission or spread of porcine endogenous retroviruses (PERV) to humans. While PERV is harmless to pigs, if it is transmitted or spread to humans, there is a potential for various diseases caused by retroviruses to occur. To address these issues, it is necessary to produce pigs in which PERV has been inactivated.

[0005] According to a recent study, 62 copies of PERV were identified in porcine kidney epithelial cell lines (PK15), and an attempt was made to multi-edit them using a CRISPR / Cas system. However, most of the cells died, and it was confirmed that PERV was inactivated in only a few of them. This represents a limited success, and additional problems such as genomic rearrangement caused by simultaneous genome editing and low efficiency still exist.

[0006] Therefore, there is a need for efficient technology to simultaneously edit multiple copies of genes to secure potential sources for organ transplantation. The problem to be solved

[0007] One objective of the present application is to provide a composition for artificially manipulating the genes of porcine endogenous retroviruses (PERV).

[0008] Another objective of the present application is to provide a method for artificially inactivating porcine endogenous retrovirus genes.

[0009] Another objective of the present application is to provide pig cells or / and pig or / and pig organs using the above method. means of solving the problem

[0010] To solve the problem of the present application described above, a method for inactivating porcine endogenous retrovirus (PERV), which exists in multiple copies in the genome of pigs, is provided.

[0011] The method includes the step of introducing a genetic engineering composition into pig cells; and

[0012] At this time, the above genetic engineering composition is,

[0013] (a) A guide RNA capable of targeting the target sequence of a target gene of PERV or a nucleic acid sequence encoding the same;

[0014] (b) Cas protein or nucleic acid sequence encoding it; and

[0015] (c) cytidine deaminase or a nucleic acid sequence encoding it;

[0016] Includes,

[0017] At this time, the target gene of the above PERV is one or more selected from the gag gene, pol gene, and env gene, and

[0018] The above target sequence comprises one or more nucleotide sequences among the nucleotide sequences of 5'-CAG-3', 5'-CAA-3', 5'-CGA-3', 5'-CTA-3', 5'-CCA-3', and 5'-TCA-3', wherein the target sequence is located in a consecutive 10bp to 30bp sequence region of the PERV gene, and

[0019] The above Cas protein is selected from the group consisting of Cas9 protein derived from Streptococcus pyogenes, Cas9 protein derived from Campylobacter jejuni, Cas9 protein derived from Streptococcus thermophiles, Cas9 protein derived from Staphylococcus aureus, Staphylococcus auricularis, and Cpf1 protein, and

[0020] The above inactivation reduces or suppresses the expression of the target gene of PERV by generating a stop codon within the target sequence, and

[0021] A method characterized by deactivating the PERV existing in multiple copies as described above may be provided.

[0022] At this time, a method may be provided characterized in that the above-mentioned stop codon is one or more nucleotide sequences selected from 5'-TAG-3', 5'-TAA-3' and 5'-TGA-3'.

[0023] To solve another problem of the present application described above, a genetic engineering composition for inactivating porcine endogenous retrovirus (PERV) is provided.

[0024] The above composition is,

[0025] (a) A guide RNA or a nucleic acid encoding the same, comprising one or more guide domain sequences selected from SEQ ID NOs: 66 to 130;

[0026] (b) Cas protein or nucleic acid sequence encoding it; and

[0027] (c) cytidine deaminase or a nucleic acid sequence encoding it;

[0028] Includes,

[0029] At this time, the target gene of the above PERV is one or more selected from the gag gene, pol gene, and env gene, and

[0030] The above guide domain can form a complementary binding with a guide nucleic acid binding target sequence among the target sequences of the PERV gene, and

[0031] The guide RNA comprises one or more nucleotide sequences of 5'-CAG-3', 5'-CAA-3', 5'-CGA-3', 5'-CUA-3', 5'-CCA-3', and 5'-UCA-3' within the guide domain sequence, and

[0032] A composition may be provided characterized in that the above Cas protein is selected from the group consisting of Cas9 protein derived from Streptococcus pyogenes, Cas9 protein derived from Campylobacter jejuni, Cas9 protein derived from Streptococcus thermophiles, Cas9 protein derived from Staphylococcus aureus, Staphylococcus auricularis, and Cpf1 protein.

[0033] In addition, to solve another problem of the present application described above, pig cells are provided.

[0034] The above pig cells are,

[0035] A porcine endogenous retrovirus (PERV) containing in its genome one or more genes selected from the gag, pol, and env genes inactivated, and

[0036] As a pig cell containing at least two stop codons within the above-mentioned inactivated gene,

[0037] The above stop codon is one or more nucleotide sequences selected from 5'-TAG-3', 5'-TAA-3', and 5'-TGA-3', and

[0038] The above-mentioned inactivated PERV exists as multiple copies within the genome, and

[0039] Pig cells characterized by a decrease in the expression level of PERV by more than 50% compared to before inactivation may be provided. That is, pig cells characterized by the presence of more than 50% of the inactivated PERV gene compared to before inactivation may be provided. Effects of the invention

[0040] According to the present application, the following effects occur.

[0041] First, according to the present application, a composition for artificially manipulating the genes of porcine endogenous retroviruses can be provided.

[0042] Second, by using the composition provided by the present application, a method for artificially inactivating the gene of a porcine endogenous retrovirus can be provided.

[0043] Third, by using the method provided by the present application, it is possible to provide pig cells or / and pig or / and pig organs in which the gene of a porcine endogenous retrovirus has been artificially manipulated. Brief explanation of the drawing

[0044] FIG. 1 is a schematic diagram of the technology of the present application. PAM refers to a protospacer adjacent motif, and UGI refers to a Uracil DNA glycosylase inhibitor. FIG. 2 is a diagram illustrating the vector used in the present application. The arrows indicate the locations of the primers used to verify the integration of the transgene used in the present application. Figure 3 is a diagram confirming the intracellular integration of the transgene of the present application. Colonies #1 and #3 each represent single-cell derived colonies obtained after Neomycin selection. Figure 4 is a diagram showing the results of confirming that a stop codon was generated in the gag gene of the PERV of the present application. Figure 5 is a diagram showing the results of confirming that a stop codon was generated in the pol gene of the PERV of the present application. Specific details for implementing the invention

[0045] Best form for carrying out the invention

[0046] The contents of this application will be explained in more detail with reference to the drawings attached to this application and the description below. The attached drawings include embodiments of the application, but do not include all embodiments. Furthermore, the contents of this application may be embodied in various forms and are not limited to the specific embodiments described below. That is, this application may be subject to various modifications and may have various embodiments. Although the structure and features of this application have been described based on embodiments according to this application, this application is not limited thereto. It is obvious to those skilled in the art that various changes or modifications may be made within the spirit and scope of this application, and therefore, it is noted that such changes or modifications fall within the scope of the appended claims.

[0047] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which the present invention pertains. Methods and materials similar or identical to those described herein may be used in the practice or testing of the present invention. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. Additionally, materials, methods, and examples are merely illustrative and are not intended to be limiting.

[0048] The term “target sequence” refers to a nucleotide sequence present within a target gene or nucleic acid, specifically a nucleotide sequence of a part of a target region within the target gene or nucleic acid, wherein the “target region” is a site within the target gene or nucleic acid that can be modified by a guide nucleic acid-editor protein. In this case, the target sequence may be a guide nucleic acid binding sequence or a guide nucleic acid non-binding sequence. Additionally, the target region is a region containing nucleotides for which base substitution is induced by a base modification enzyme. The term “target region” may be used interchangeably with “target site.”

[0049] The above “guide nucleic acid-binding sequence” is a nucleotide sequence having partial or complete complementarity with a guide sequence included in the guide domain of a guide nucleic acid, and can form a complementary binding with a guide sequence included in the guide domain of a guide nucleic acid. The term guide nucleic acid-binding sequence may be used interchangeably with guide nucleic acid-binding target sequence.

[0050] The above “guide nucleic acid-non-binding sequence” is a nucleotide sequence having partial or complete homology with the guide sequence included in the guide domain of the guide nucleic acid, and cannot form a complementary binding with the guide sequence included in the guide domain of the guide nucleic acid. The term guide nucleic acid-non-binding sequence may be used interchangeably with guide nucleic acid-non-binding target sequence.

[0051] In the following, the term "target sequence" may be used to mean both types of nucleotide sequence information. For example, in the case of a target gene, the target sequence may mean the sequence information of the transcribed strand of the target gene DNA, or the nucleotide sequence information of the non-transcribed strand.

[0052] The term “targeting” refers to a complementary binding to a guide nucleic acid binding sequence among target sequences present in a target gene or nucleic acid. In this case, the complementary binding may be a 100% complete complementary binding, or an incomplete complementary binding of 70% or more but less than 100%. Therefore, “targeting gRNA” refers to a gRNA that binds complementarily to a guide nucleic acid binding sequence among target sequences present in a target gene or nucleic acid.

[0053] The term “artificially modified or engineered or artificially engineered” refers to a state that has been artificially modified, rather than the state in which it exists as it does in nature. Hereinafter, the unnatural, artificially modified or engineered Porcine Endogenous Retrovirus (PERV) gene may be used interchangeably with the term artificially modified PERV gene. The above unnatural, artificially modified or engineered PERV gene may be used to mean one or more genes selected from the artificially modified or engineered gag gene, the artificially modified or engineered pol gene, and the artificially modified or engineered env gene.

[0054] The term “PERV gene” means including both the RNA genome sequence of PERV and its DNA corresponding sequence, for example, including the cDNA sequence transcribed by the RNA genome sequence of PERV, the double-stranded DNA sequence generated by the cDNA sequence, and the DNA sequence inserted into the host cell genome. Additionally, PERV gene may be used interchangeably with the genome of PERV.

[0055] The term “inactivation or deactivation” means a state in which a target nucleic acid or gene has been artificially manipulated. In particular, it means i) a state in which a target site within the target nucleic acid or gene is cleavaged and its function is reduced and / or lost; and ii) a state in which transcription and / or translation of the target nucleic acid or gene is not performed and / or is repressed and / or reduced.

[0056] The above inactivation can suppress or reduce the occurrence of disease by regulating the expression of target genes, nucleic acids, or proteins through the inactivation of disease-causing genes or genes having abnormal functions. For example, when a PERV gene is inactivated, it should be interpreted to include both of the following: i) a state in which the target site within the PERV gene is cleaved, resulting in reduced or lost function; and ii) a state in which the transcription and / or translation of the target gene among the PERV genes is suppressed or reduced, resulting in reduced and / or suppressed expression of the gene or protein. In particular, in this application, the term "inactivation of PERV" should be interpreted as a state in which expression is reduced and / or suppressed by suppressing the transcription and / or translation of the target gene of the PERV through the artificial generation of a stop codon.

[0057] I. Summary of the Technical Features of the Present Application

[0058] The present application relates to a composition and method capable of artificially manipulating porcine endogenous retroviruses (PERVs) that exist in multiple copies in the porcine genome, and in particular, is characterized by inactivating PERVs by causing a stop codon to form within a target sequence.

[0059] Specifically, in this application, a sequence capable of forming a stop codon by a single base substitution is found in the target sequence within the target region of the PERV in the porcine genome targeted, and a base modification enzyme capable of inducing or causing a single base substitution is used.

[0060] In order to manipulate the sequence within the target region of PERV into a stop codon in this manner, a CRISPR / Cas system and a base modification enzyme, such as deaminase, that induces or causes a single nucleotide substitution are used together. According to the method of the present application, the gag, pol, and env genes of PERV present in the porcine genome are designated as specific target regions, and a stop codon is specifically formed in the corresponding target region, thereby producing the effect of inactivating PERV.

[0061] Therefore, the present application has the following technical features.

[0062] i) By using the CRISPR / Cas system, specific genes of PERV can be targeted specifically.

[0063] ii) By using a CRISPR / Cas system to site-specifically target a specific gene of PERV and in combination with a base modification enzyme that induces or generates a single base substitution, a stop codon can be artificially generated at the target location. The generated stop codon acts during the transcription or translation process of the specific gene of PERV, thereby suppressing the expression of the specific gene of PERV.

[0064] iii) By targeting specific genes of PERV, it has high efficiency and accuracy specific to the target sequence and simultaneously generates a stop codon to suppress PERV expression, so even if PERV exists in multiple copies, cells do not die, thus providing a safe effect.

[0065] In particular, the invention sought to overcome the problem of conventional technology, which is that the efficiency of artificially manipulating cells is low, such as when multiple copies of PERV are simultaneously knocked out and inactivated, causing the cells themselves to die easily.

[0066] To explain this in more detail, it is as follows.

[0067] II. Technical (Operating) Principle of the Present Application

[0068] While there is an urgent global demand for organ xenotransplantation, immunological factors, which serve as a major barrier, remain a significant issue. This problem has also been observed in germ-free pigs, which are currently in the spotlight for xenotransplantation. With reports indicating the potential for Peripheral Emission Viruses (PERVs) present in the germ-free pig genome to infect human cells in vitro, significant efforts are being made to address this issue. However, PERVs exist in multiple copies across all pig genomes in the form of proviruses or viral particles, and they are difficult to control as they spread through the germline. Therefore, efficient measures are required to prevent PERVs from infecting human cells in vitro.

[0069] To solve the above problem, the present application inactivates PERV by using a CRISPR / Cas system and a base modification enzyme together.

[0070] In particular, the present application is characterized by using a CRISPR / Cas system that cuts DNA (e.g., gRNA and Cas nickase) and a base modifying enzyme (e.g., deaminase) together.

[0071] Refer to the schematic diagram in FIG. 1 for the principle of inactivating PERV of the present application. In FIG. 1, nCas9 and cytidine deaminase are described as examples. FIG. 1 illustrates the technical principle of the present application by way of example and is not limited thereto.

[0072] Referring to Figure 1, the principle of inactivating PERV present in the pig genome is as follows.

[0073] To inactivate PERV, a CRISPR / Cas system containing gRNA and Cas9 nickase is required to target the target gene or nucleic acid of PERV. Additionally, cytidine deaminase and a uracil DNA glycosylase inhibitor are required to generate a stop codon by substituting cytosine (C) with thymine (T).

[0074] In Figure 1, gRNA targets a target sequence containing the 5'-CAG-3' sequence and the PAM sequence, and interacts with Cas9 nickase so that Cas9 nickase cleaves a single strand of the target site.

[0075] In order to generate a stop codon by substituting a specific base of the target sequence intended in the present application, nickase Cas9 (nCas9) is used, which cleaves the opposite strand of the strand where the stop codon is generated while maintaining the characteristic of Cas9 that recognizes the target sequence.

[0076] Based on this, when cytidine deaminase is used with Cas9 nickase, cytidine deaminase and UGI act on the opposite strand of the DNA strand cut by Cas9 nickase, causing cytidine in the 5'-CAG-3' sequence within the target sequence to be replaced with thymine and changed to the 5'-TAG-3' sequence. As a result, the target sequence acquires the 5'-TAG-3' sequence, which is the stop codon sequence, thereby inactivating the target nucleic acid or gene.

[0077] The detailed explanation regarding this is as follows.

[0078] The gRNA of the CRISPR / Cas system binds to a target nucleic acid or gene sequence (target in Fig. 1) and interacts with Cas9 nickase, causing Cas9 nickase to cleave a single strand of the target site (scissor shape in Fig. 1), thereby inactivating PERV. That is, by utilizing the CRISPR / Cas system in this application, the cleavage is not only specific to the target gene within the porcine genome but also has the characteristic of occurring specifically at a specific location of the target gene.

[0079] In this way, since the gRNA of the CRISPR / Cas system can recognize target genes, it can target the gag, pol, and env genes, which are the genes of PERV present in the porcine genome that play the most important role in replication. Furthermore, by the Cas9 nickase cleaving the target site of the target gene, the CRISPR / Cas system for PERV inactivation of the present application can specifically target the desired gene.

[0080] At this time, since Cas9 nickase recognizes the PAM (Protospacer adjacent motif) sequence, the target sequence must contain the PAM sequence.

[0081] gRNA can be designed by considering the above PAM sequence. Briefly explaining the design method, a region containing a PAM sequence is identified within the target nucleic acid or gene sequence, and a sequence of approximately 20 bp is selected from that PAM sequence to design the gRNA.

[0082] Meanwhile, the present application uses cytidine deaminase together with a CRISPR / Cas system for PERV inactivation. In particular, the purpose is to achieve the objective of making a specific sequence of a target gene or target sequence within a nucleic acid targeted by the CRISPR / Cas system become a stop codon by using a CRISPR / Cas system and a base modification enzyme (e.g., cytidine deaminase and UGI) together so that cytosine is substituted with thymine.

[0083] Cytidine deaminase is an enzyme that has the activity of substituting cytosine with thymine, and in one embodiment, converts cytosine located on the strand where the PAM sequence exists within the target sequence into thymine.

[0084] At this time, to increase the efficiency of base substitution, UGI, a protein that inhibits the enzyme (Uracil DNA glycosylase; UDG) that converts uracil (U) to cytosine, is additionally used along with cytidine deaminase. In this case, UGI plays a role in inhibiting the restoration of uracil, an intermediate product of deamination caused by cytidine deaminase, to cytosine by UDG. Subsequently, during DNA replication or mismatch-repair processes using the strand containing uracil as a template, guanine (G) on the opposite strand is substituted with adenine (A), resulting in a single base pair substitution from a CG pair to a TA pair. In one embodiment, through the action of the CRISPR / Cas system, cytidine deaminase, and UGI, cytosine located on the strand containing the PAM sequence within the target sequence is substituted with thymine.

[0085] Since cytidine deaminase is an enzyme involved in converting cytosine into thymine, considering this, a target sequence comprising one or more nucleotide sequences selected from, for example, 5'-CAG-3', 5'-CAA-3', 5'-CGA-3', 5'-CTA-3', 5'-CCA-3', and 5'-TCA-3', which are sequences that can be converted into stop codon sequences in the target sequence, may be used in the present application.

[0086] In this way, when the CRISPR / Cas system and deaminase work together, the CRISPR / Cas system targets one or more of the gag, pol, and env genes of PERV to cleave the target site, and a stop codon is formed within the target sequence, thereby inhibiting the transcription or / and translation of one or more of the PERV genes and reducing or / and inhibiting the expression of the PERV genes, which can further enhance the PERV inactivation effect.

[0087] Hereinafter, a composition for manipulating PERV having the technical features of the present application and a method for inactivating PERV using the same will be described in more detail.

[0088] III. Genetic engineering composition for PERV inactivation

[0089] One aspect disclosed by the present application relates to a composition for genetic engineering for artificially inactivating the PERV described above. The composition for genetic engineering can be used to generate an artificially engineered PERV gene. In addition, the PERV gene artificially engineered by the composition for genetic engineering can control the transfer of the PERV gene and the expression of a protein encoded by the PERV gene.

[0090] 1) Target gene

[0091] The target gene targeted by the above-mentioned gene manipulation composition of the present application is PERV.

[0092] PERVs exist in multiple copies on all types of pig genomes in the form of proviruses or viral particles, and are difficult to control as they are transmitted through the germline. PERVs refer to endogenous retroviruses that are inserted into the pig genome and are transmitted to the next generation according to Mendel's laws of inheritance, and are also transmitted through infection.

[0093] PERV is Retroviridae class Gammaretrovirus It is classified into a genus and, based on its nucleotide and amino acid sequences and morphology, belongs to the gamma-retrovirus group, similar to the murine leukemia virus and feline leukemia virus that cause leukemia or immunodeficiency. The aforementioned viruses undergo germline translocation and show no symptoms in pigs; most exist in a form incapable of producing actual viruses due to gene deletions or mutations.

[0094] Replicable subtypes of PERV include PERV-A, PERV-B, and PERV-C.

[0095] While PERV-A and PERV-B can infect human cells, pig cells, and cells of other species, PERV-C is reported to partially infect only pig cells and human cells called HT1080 (Takeuchi et al., 1998). Some studies have confirmed that a virus recombined with PERV-C as a template and only the receptor binding site as PERV-A exhibits 500 times greater infectivity against human cells (Birke et al., 2004; Harrison et al., 2004; Scobie et al., 2004). Additionally, it has been reported that humanized PERV, once infected with human cells, has increased infectivity to human cells compared to PERV produced in pig cells.

[0096] For example, the gene manipulation composition of the present application can simultaneously target any two or more subtypes selected from PERV-A, PERV-B, and PERV-C.

[0097] The target gene disclosed by the present application may be a portion of the gene included in the PERV gene.

[0098] The target gene disclosed by the present application may be the gag gene among the PERV genes.

[0099] The target gene disclosed by the present application may be the pol gene among the PERV genes.

[0100] The target gene disclosed by the present application may be the env gene among the PERV genes.

[0101] The PERV gene includes the gag gene, the pol gene, and the env gene. These are the genes that play the most important role in PERV replication. Specifically, the gag gene, the pol gene, and the env gene are known. Specifically, the gag gene encodes the core protein, the pol gene encodes the reverse transcriptase, and the env gene encodes the coat protein.

[0102] Among these, the gag and pol genes, which form the enzyme and structural proteins of the virus, show more than 90% similarity in PERV-A, PERV-B, and PERV-C, whereas the similarity of the env gene, which is involved in infection into host cells, shows a large difference.

[0103] The target genes disclosed by the present application may be two or more genes selected from the gag gene, pol gene, and env gene among the PERV genes.

[0104] For example, when the pol gene and gag gene of PERV are targeted and inactivated, i) the pol gene region involved in reverse transcription and replication is inactivated, thereby inhibiting reverse transcription and replication, and ii) at the same time, the gag gene encoding a core protein essential for growth is inactivated, thereby blocking the production of viral particles.

[0105] The target genes disclosed by the present application may be the gag gene, pol gene, and env gene among the PERV genes.

[0106] The target gene disclosed by the present application may be two or more genes selected from the gag gene, pol gene, and env gene among the genes of the PERV subtype.

[0107] The above PERV gene may exist within the genome of pig cells as the whole genome sequence or partial nucleic acid sequence of PERV.

[0108] At this time, the above-mentioned partial nucleic acid sequence may be the entire nucleic acid sequence of one or more of the gag gene, pol gene and env gene.

[0109] At this time, the above-mentioned partial nucleic acid sequence may be a partial nucleic acid sequence of one or more of the gag gene, pol gene and env gene.

[0110] The PERV gene can exist in 1 to 100 copies within the genome of pig cells.

[0111] At this time, the above PERV gene may be the whole genome sequence or a partial nucleic acid sequence of PERV.

[0112] At this time, 1 to 100 copies of the PERV gene may exist in the genome of the pig cells in a continuous and / or discontinuous manner.

[0113] For example, if there are 60 copies of the above-mentioned PERV gene in the genome of a pig cell, 10 copies may exist consecutively and the remaining 50 copies may each exist discontinuously. Or, if there are 20 copies of the above-mentioned PERV gene in the genome of a pig cell, 10 copies may exist consecutively and the remaining 10 copies may also exist consecutively, but the two groups of the 10 consecutive copies may exist discontinuously.

[0114] At this time, 1 to 100 copies within the genome of the pig cell may exist as a mixture of the full genome sequence and some nucleic acid sequences of PERV.

[0115] For example, if there are 5 copies of the above-mentioned PERV gene within the genome of a pig cell, 2 copies may exist as the full genome sequence of PERV, and the remaining 3 copies may exist as partial nucleic acid sequences. Or, if there are 13 copies of the above-mentioned PERV gene within the genome of a pig cell, 5 copies may exist as the full genome sequence of PERV, 4 copies may exist as the full nucleic acid sequence of the gag gene among the PERV genes, and the remaining 4 copies may exist as partial nucleic acid sequences of the pol gene among the PERV genes.

[0116] As previously explained, for the CRISPR / Cas system included in the gene manipulation composition of the present application to operate, the target sequence of the target gene must contain a PAM (Protospacer adjacent motif) sequence.

[0117] This is because, in the CRISPR / Cas system, the Cas protein recognizes the PAM sequence; therefore, for it to function, the PAM sequence must be included within the target sequence. Specifically, a guide nucleic acid non-binding sequence is located in a region adjacent to the PAM sequence, while a guide nucleic acid binding sequence exists on the opposite strand.

[0118] Therefore, for the CRISPR / Cas system to operate, the target sequence within the target gene can be determined based on PAM. Consequently, since the target gene of the present application is designed to enable the operation of the CRISPR / Cas system, the location of the target gene has PAM-specific characteristics.

[0119] In an example of implementation,

[0120] The target sequence disclosed by the present application, i.e., the guide nucleic acid non-binding sequence, may be a sequence of 10 to 35 consecutive nucleotides adjacent to the 5' end and / or 3' end of the PAM sequence within the nucleic acid sequence of the target gene.

[0121] At this time, the above PAM sequence may be, for example, one or more of the following sequences (described in the 5' to 3' direction).

[0122] NGG (N is A, T, C or G);

[0123] NNNNRYAC (N is independently A, T, C, or G, R is A or G, and Y is C or T);

[0124] NNGG (N is independently A, T, C, or G);

[0125] NNAGAAW (N is independently A, T, C, or G, and W is A or T);

[0126] NNNNGATT (N is independently A, T, C, or G);

[0127] NNGRR(T) (N is independently A, T, C, or G, and R is A or G); and TTN (N is A, T, C, or G).

[0128] For example, the target sequence (guide nucleic acid non-binding sequence) may be a sequence of 10 to 35 consecutive nucleotides adjacent to the 5' end and / or 3' end of the PAM sequence within the nucleic acid sequence of the PERV gene.

[0129] As another example, the target sequence may be a sequence of 10 to 35 consecutive nucleotides adjacent to the 5' end and / or 3' end of the PAM sequence within the nucleic acid sequence of the gag gene.

[0130] As another example, the target sequence may be a sequence of 10 to 35 consecutive nucleotides adjacent to the 5' end and / or 3' end of the PAM sequence within the nucleic acid sequence of the pol gene.

[0131] As another example, the target sequence may be a sequence of 10 to 35 consecutive nucleotides adjacent to the 5' end and / or 3' end of the PAM sequence within the nucleic acid sequence of the env gene.

[0132] In addition, in the present application, the target sequence of the target gene must include a sequence capable of base substitution with a stop codon within the sequence. The base substitution may be performed by a base modifying enzyme that induces or causes a single base substitution.

[0133] At this time, the above base modifying enzyme may be deaminese.

[0134] For example, deaminases may include cytidine deaminase, which changes (substitutes) cytosine to thymine, and adenosine deaminase, which substitutes adenine to guanine.

[0135] For convenience, the following description focuses on cytidine diaminese, which changes cytosine into thymine.

[0136] For example, when the above cytidine deaminase is actuated on a target sequence, cytosine among the sequences capable of base substitution into a stop codon within the target sequence is substituted with thymine, thereby generating a stop codon.

[0137] In one embodiment, the PERV sequence targeted by the present application is a stop codonization target sequence and comprises one or more nucleotide sequences selected from 5'-CAG-3', 5'-CAA-3', 5'-CGA-3', 5'-CTA-3', 5'-CCA-3', and 5'-TCA-3'. This is described in [Table 1] and [Table 2] below.

[0138] The above stop codonization target sequence may be included in the guide nucleic acid non-binding sequence of the PERV target gene in the 5' to 3' direction (Table 1); or may not be included in the guide nucleic acid binding sequence on the opposite strand. For illustrative purposes, the strand containing the guide nucleic acid non-binding sequence is designated as the first strand, and the opposite strand (containing the guide nucleic acid binding sequence) is designated as the second strand.

[0139] i) A stop codonization target sequence included in the target sequence of the first strand for generating a stop codon on the first strand:

[0140] In this application, a case may be considered in which the 5'-to-3' direction strand of the targeted PERV (i.e., the guide nucleic acid non-binding sequence) contains one or more nucleotide sequences selected from 5'-CAG-3', 5'-CAA-3', and 5'-CGA-3'. In this case, when cytidine deaminase substituting cytosine with thymine is activated, it changes to the stop codons 5'-TAG-3', 5'-TAA-3', and 5'-TGA-3' (Table 1).

[0141] The stop codonization target sequence included in the target sequence of the first strand After cytidine deaminease treatment Change sequence 5'-CAG-3' → 5'-TAG-3' 5'-CAA-3' → 5'-TAA-3' 5'-CGA-3' → 5'-TAA-3'

[0142] ii) A stop codonization target sequence included in the target sequence of the first strand for generating a stop codon on the second strand:

[0143] In the same context, we can consider the case where a stop codon is generated on the opposite strand (second strand) of the first strand in [Table 1]. In other words, the first strand in [Table 1] may contain one or more nucleotide sequences selected from 5'-CTA-3', 5'-CCA-3', and 5'-TCA-3' as the sequences to be stopped. At this time, when cytidine deaminase is activated, cytosine (C) is substituted with thymine (T), and the sequences are changed to 5'-TTA-3'. When DNA replication or repair occurs using the first strand containing the modified sequence (5'-TTA-3') as a template, in the second strand, the sequences complementary to the sequence to be stopped (3'-GAT-5', 3'-GGT-5', 3'-AGT-5') are changed to 3'-AAT-5', which is the sequence complementary to the modified sequence (5'-TTA-3'). That is, the stop codon 5'-TAA-3' is generated in the second strand (Table 2).

[0144] The target sequence for stop codonization included in the target sequence of the first strand After cytidine deaminease treatment Included in the first strand altered sequence The stop codon sequence contained in the second strand complementary to the altered sequence 5'-CTA-3' → 5'-TTA-3' 3'-AAT-5' 5'-CCA-3' → 5'-TTA-3' 3'-AAT-5' 5'-TCA-3' → 5'-TTA-3' 3'-AAT-5'

[0145] The target sequence targeted in this application is a sequence that takes into account both the PAM sequence for the CRISPR / Cas system to operate and the sequence in which a base modifying enzyme can operate to generate a stop codon (hereinafter referred to as the stop codonization target sequence).

[0146] The target sequence targeted in this application is a sequence that takes into account both the PAM sequence for the CRISPR / Cas system to operate and the sequence in which a base modifying enzyme can operate to generate a stop codon (hereinafter referred to as the stop codonization target sequence).

[0147] Accordingly, through [Table 1] and [Table 2] above, the target sequence of the present application must be a sequence that includes at least one nucleotide sequence selected from 5'-CAG-3', 5'-CAA-3', 5'-CGA-3', 5'-CTA-3', 5'-CCA-3' and 5'-TCA-3', which are stop codonization target sequences.

[0148] In one embodiment,

[0149] The target sequence disclosed by the present application may be a sequence of 10 to 35 consecutive nucleotides containing 5'-CAG-3' within the nucleic acid sequence of the target gene.

[0150] The target sequence disclosed by the present application may be a sequence of 10 to 35 consecutive nucleotides containing 5'-CAA-3' within the nucleic acid sequence of the target gene.

[0151] The target sequence disclosed by the present application may be a sequence of 10 to 35 consecutive nucleotides containing 5'-CGA-3' within the nucleic acid sequence of the target gene.

[0152] The target sequence disclosed by the present application may be a sequence of 10 to 35 consecutive nucleotides containing 5'-CTA-3' within the nucleic acid sequence of the target gene.

[0153] The target sequence disclosed by the present application may be a sequence of 10 to 35 consecutive nucleotides containing 5'-CCA-3' within the nucleic acid sequence of the target gene.

[0154] The target sequence disclosed by the present application may be a sequence of 10 to 35 consecutive nucleotides containing 5'-TCA-3' within the nucleic acid sequence of the target gene.

[0155] Hereinafter, examples of target sequences that can be used in one embodiment of the present invention are summarized in [Table 3], and the target sequences described in [Table 3] are guide nucleic acid non-binding sequences, and through the described sequences, complementary sequences, i.e., guide nucleic acid binding sequences, can be predicted.

[0156] Name Target gene Direction Target (5' to 3', w / o PAM) SEQ ID NO PERV-gag-1 gag + ttcaggttaagaagggacct SEQ ID NO: 1 PERV-gag-2 gag + gcagacactcttcacagccg SEQ ID NO: 2 PERV-gag-3 gag + ccagaaagcctcagtggccc SEQ ID NO: 3 PERV-gag-4 gag + tcagagactggaagggttac SEQ ID NO: 4 PERV-gag-6 gag - agccatggtttaacccatgg SEQ ID NO: 5 PERV-gag-7 gag - tcccaaccgaggcgagtcaa SEQ ID NO: 6 PERV-gag-8 gag - gtcccaaccgaggcgagtca SEQ ID NO: 7 PERV-gag-9 gag + tccccgaatcctggctcttg SEQ ID NO: 8 PERV-gag-10 gag + gcgagagagaattctgttag SEQ ID NO: 9 PERV-gag-11 gag + tccccaacgcctcacggggt SEQ ID NO: 10 PERV-gag-12 gag + ccaacgcctcacggggttgg SEQ ID NO: 11 PERV-gag-13 gag + gttgcaaaatgagattgaca SEQ ID NO: 12 PERV-gag-14 gag + ttgcaaaatgagattgacat SEQ ID NO: 13 PERV-pol-1 pol + ggagcagtttccccaagcct SEQ ID NO: 14 PERV-pol-2 pol + cccacaggttattcaactga SEQ ID NO: 15 PERV-pol-3 pol + acagtaccccttgagtagag SEQ ID NO: 16 PERV-pol-4 pol + ggtgcaggacatacacccaa SEQ ID NO: 17 PERV-pol-5 pol + ggcccagatttgcaggagag SEQ ID NO: 18 PERV-pol-6 pol + cgggcagcgatggctgacgg SEQ ID NO: 19 PERV-pol-7 pol + gacagtacaccctagaagac SEQ ID NO: 20 PERV-pol-8 pol + agaccagttctctgagactc SEQ ID NO: 21 PERV-pol-9 pol + ccagttctctgagactccgg SEQ ID NO: 22 PERV-pol-10 pol + cagttctctgagactccgga SEQ ID NO: 23 PERV-pol-11 pol - ccagttccgttcaggcggga SEQ ID NO: 24 PERV-pol-12 pol - accagttccgttcaggcggg SEQ ID NO: 25 PERV-pol-13 pol - tgtaccagttccgttcaggc SEQ ID NO: 26 PERV-pol-14 pol - ctccattcgaaggcaaaaag SEQ ID NO: 27 PERV-pol-15 pol - cctccatggtcctagggttt SEQ ID NO: 28 PERV-pol-16 pol - tcctccatggtcctagggtt SEQ ID NO: 29 PERV-pol-17 pol - cttcccagtgagcgcctggg SEQ ID NO: 30 PERV-pol-18 pol - ccagtattttttagccacca SEQ ID NO: 31 PERV-pol-19 pol - cttcagttgaataacctgtg SEQ ID NO: 32 PERV-pol-20 pol - ttctaagcagtcctgtttgg SEQ ID NO: 33 PERV-pol-21 pol - tcctagggtgtactgtcgtc SEQ ID NO: 34 PERV-pol-22 pol + agcgatggctgacggaggca SEQ ID NO: 35 PERV-pol-23 pol + gctcaaatttcttttgaaca SEQ ID NO: 36 PERV-pol-24 pol + tcaagatatacagtcctggt SEQ ID NO: 37 PERV-pol-25 pol + caagcctgggcagaaaccgc SEQ ID NO: 38 PERV-pol-26 pol + tgttcaaagattaatccaac SEQ ID NO: 39 PERV-pol-27 pol + gttcaaagattaatccaaca SEQ ID NO: 40 PERV-pol-28 pol + aaacaagtgagagagttttt SEQ ID NO: 41 PERV-pol-29 pol + aacaagtgagagagtttttg SEQ ID NO: 42 PERV-pol-30 pol + cccaaaccctaggaccatgg SEQ ID NO: 43 PERV-pol-31 pol + caactattgattgaggagac SEQ ID NO: 44 PERV-pol-32 pol + agcgcaaaaggctgagctca SEQ ID NO: 45 PERV-pol-33 pol + caagctttgcggctggccga SEQ ID NO: 46 PERV-pol-34 pol + tccgagatttggaataccta SEQ ID NO: 47 PERV-env-1 env + aacaggaaaatattcaaaag SEQ ID NO: 48 PERV-env-2 env + tgaacaggggcccccggccc SEQ ID NO: 49 PERV-env-3 env + cagcagctagagaaaggact SEQ ID NO: 50 PERV-env-4 env + accaggggtggtttgaagga SEQ ID NO: 51 PERV-env-5 env - ccagcttaacgtgggatgca SEQ ID NO: 52 PERV-env-6 env - tttccagtctccatcgttgg SEQ ID NO: 53 PERV-env-7 env - ccatttccagtctccatcgt SEQ ID NO: 54 PERV-env-8 env - gcccaccacctgttataacc SEQ ID NO: 55 PERV-env-9 env - accatccttcaaaccacccc SEQ ID NO: 56 PERV-env-10 env + actcgaggtgttgctcctag SEQ ID NO: 57 PERV-env-11 env + ccgagtgtactaccatcctg SEQ ID NO: 58 PERV-env-12 env + taccaaggccttctgagcca SEQ ID NO: 59 PERV-env-13 env - gtctataaggcgtttactac SEQ ID NO: 60 PERV-env-14 env - gaccatgacacagaaatctt SEQ ID NO: 61 PERV-env-15 env - accatccttcaaaccacccc SEQ ID NO: 62 PERV-env-16 env - acccactcgttctctaacaa SEQ ID NO: 63 PERV-env-17 env - cgtcagagcagaaagcaggg SEQ ID NO: 64 PERV-env-18 env - tcctatgcatgtccccttcc SEQ ID NO: 65

[0157] 2) 에디터단백질

[0158] The gene manipulation composition disclosed by the present application may include an editor protein.

[0159] For a detailed description of the guide nucleic acid, editor protein, and guide nucleic acid-editor protein complex to be described below, refer to Korean Published Patent No. 2018-0054427 and Korean Published Patent No. 2018-0136914.

[0160] Additionally, for a specific description of base modification enzymes, refer to Korean Published Patent No. 2020-0135225.

[0161] The above “editor protein” means a peptide, polypeptide, or protein capable of artificially manipulating (editing) the genome or nucleic acid within a target cell.

[0162] The above editor protein may be a cutting enzyme or a fusion protein containing it.

[0163] The above fusion protein may consist of a cutting enzyme and one or more enzymes that have different functions from the cutting enzyme.

[0164] One or more enzymes having a different function from the above-mentioned cutting enzyme may be one or more enzymes selected from base modifying enzymes, methylation regulating enzymes, phosphorylation regulating enzymes, and acetylation regulating enzymes.

[0165] At this time, the cutting enzyme may be a polypeptide or protein that functions to cut nucleic acids, genes, or chromosomes.

[0166] At this time, the base modifying enzyme may be a polypeptide or protein that functions to modify the bases of nucleotides constituting nucleic acids into other bases.

[0167] At this time, the methylation regulating enzyme may be a polypeptide or protein that functions to methylate and / or demethylate the nucleotide sequence of a nucleic acid, gene, or chromosome.

[0168] At this time, the phosphorylation regulating enzyme may be a polypeptide or protein that functions to phosphorylate and / or dephosphorylate the nucleotide sequence of nucleic acid, gene, or chromosome.

[0169] At this time, the acetylation regulating enzyme may be a polypeptide or protein that functions to acetylate and / or deacetylate the nucleotide sequence of nucleic acid, gene, or chromosome.

[0170] In addition, the editor protein may further include additional domains, peptides, polypeptides, or proteins.

[0171] The additional domain, peptide, polypeptide, or protein mentioned above may be a functional domain, peptide, polypeptide, or protein having the same or different function as the functional domain, peptide, polypeptide, or protein included in the editor protein.

[0172] In one embodiment, the editor protein comprises a CRISPR enzyme.

[0173] In the present application, the CRISPR enzyme may be derived from Streptococcus pyogenes, Streptococcus thermophilus, Streptococcus sp., Staphylococcus aureus, or Campylobacter jejuni (Cj).

[0174] The above CRISPR enzyme may be Cas9, Cpf1, or nickase, but is not limited thereto.

[0175] For the structural characteristics of the above Cas9, refer to Hiroshi Nishimasu et al. (2014) Cell 156:935-949.

[0176] For the structural characteristics of the above Cpf1, refer to Takashi Yamano et al. (2016) Cell 165:949-962.

[0177] The above nickase refers to a CRISPR enzyme engineered or modified to cleave only one strand of the double strand of a target gene or nucleic acid, and the nickase has nuclease activity that cleaves a single strand, for example, the non-complementary or complementary strand of the gRNA of the target gene or nucleic acid. Therefore, two nuclease activities are required to cleave the double strand.

[0178] The above CRISPR enzyme recognizes a specific nucleotide sequence within a target gene or nucleic acid, namely PAM (Protospacer adjacent motif), or interacts with PAM.

[0179] For example, the above Cas9 protein recognizes a PAM (proto-space radjacent Motif) sequence on the target genome DNA sequence and functions to cut the DNA sequence at a location adjacent to the PAM sequence by interacting with a guide nucleic acid. Although it is generally understood that the PAM is determined by the origin of the above CRISPR enzyme, the PAM may change as research on mutations of the enzyme of that origin is conducted.

[0180] For example, if the CRISPR enzyme is SpCas9, PAM may be 5'-NGG-3'; if it is Streptococcus thermophilus Cas9 (StCas9), PAM may be 5'-NNAGAAW-3' (W = A or T); if it is Neisseria meningiditis Cas9 (NmCas9), PAM may be 5'-NNNNGATT-3'; if it is Campylobacter jejuni Cas9 (CjCas9), PAM may be 5'-NNNNRYAC-3' (V = G or C or A, R = A or G, Y = C or T); and if it is Staphylococcus aureus Cas9 (SaCas9), PAM may be 5'-NNGRR(T)-3', where N is independently A, T, C or G, and R can be A or G. In addition, in the case of Staphylococcus auricularis Cas9 (SauriCas9), the PAM may be 5'-NNGG-3', where N is A, T, G, or C; or A, U, G, or C. As another example, when the CRISPR enzyme is Cpf1, the PAM sequence may be 5'-TTN-3' (N is A, T, C, or G).

[0181] The editor protein of the present application further includes a base modifying enzyme.

[0182] The above base modifying enzyme may be a polypeptide or protein that functions to modify the bases of nucleotides constituting nucleic acids into other bases.

[0183] The above base modifying enzyme may be deaminase.

[0184] The above deaminase may be a wild type or a variant. The above deaminase variant may be an enzyme with increased deaminase activity compared to the wild type deaminase.

[0185] For example, a deaminase variant may be an enzyme in which one or more amino acid sequences within the deaminase are modified. In this case, the modification may be any one selected from the substitution, deletion, and insertion of amino acids.

[0186] The above deaminase can modify (substitute) one or more bases selected from adenine (A), guanine (G), cytosine (C), thymine (T), and uracil (U) into other bases.

[0187] For example, if one or more selected bases are adenine (A), the selected base may be modified to guanine (G), cytosine (C), thymine (T), or uracil (U). Or, if one or more selected bases are guanine (G), the selected base may be modified to adenine (A), cytosine (C), thymine (T), or uracil (U). Or, if one or more selected bases are cytosine (C), the selected base may be modified to adenine (A), guanine (G), thymine (T), or uracil (U). Or, if one or more selected bases are thymine (T) or uracil (U), the selected base may be modified to adenine (A), guanine (G), or cytosine (C).

[0188] The above deaminase may be adenosine deaminase, cytidine deaminase, cytosine deaminase, or guanine deaminase.

[0189] For example, the above deaminase may be AID, PmCDA1, AICDA, ARP2, CDA2, HIGM2, APOBEC1, APOBEC2, APOBEC3A, APOBEC3B, APOBEC3C, APOBEC3D, APOBEC3E, APOBEC3F, APOBEC3G, APOBEC3H, AICDA, CDA, DCTD, AMPD1, ADAT, ADAT2, ADAR, ADAR2, ADA, TadA, or GDA.

[0190] In one specific example, the above cytidine deaminese can substitute cytosine with thymine.

[0191] In another specific example, the adenosine deaminase can substitute adenine with guanine.

[0192] For example, the deaminese of the present application may be cytidine deaminese.

[0193] The above cytidine deaminese may be AID, PmCDA1, AICDA, ARP2, CDA2, HIGM2, APOBEC1, APOBEC2, APOBEC3A, APOBEC3B, APOBEC3C, APOBEC3D, APOBEC3E, APOBEC3F, APOBEC3G, APOBEC3H, CDA, or DCTD.

[0194] The above deaminase can generate a specific codon sequence. In this case, the specific codon sequence may be one or more stop codon sequences selected from 5'-TAG-3', 5'-TAA-3', and 5'-TGA-3'.

[0195] In one specific example, in the case of cytidine deaminase, if the target sequence in the target gene or nucleic acid contains one or more nucleotide sequences selected from 5'-CAG-3', 5'-CAA-3', 5'-CGA-3', 5'-CTA-3', 5'-CCA-3', and 5'-TCA-3', cytosine can be substituted with thymine to generate the stop codon sequence in the target gene or nucleic acid.

[0196] For example, one or more bases can be substituted with the above-mentioned base modifying enzyme to generate a stop codon.

[0197] For example, one or more bases can be substituted with the above-mentioned base modifying enzyme to induce the generation of a stop codon.

[0198] The above termination codon may be 5'-TAG-3', 5'-TAA-3' and / or 5'-TGA-3'.

[0199] The editor protein of the present application may further include a DNA glycosylase inhibitor.

[0200] The above DNA glycosylase inhibitor can further increase the efficiency of base modification.

[0201] For example, the above DNA glycosylase inhibitor may be a uracil glycosylase inhibitor (UGI) that inhibits the enzyme converting uracil to cytosine.

[0202] When base substitution occurs, the deaminase and DNA glycosylase inhibitors may be involved sequentially or simultaneously.

[0203] For example, the cytidine deaminase deaminates cytosine to provide an intermediate product, uracil. The provided uracil inhibits the mechanism by which it is restored to cytosine by UGI, and as a result, cytosine can be substituted with thymine by DNA replication or mismatch repair.

[0204] Meanwhile, for example, the editor protein of the present application may include a CRISPR enzyme and a base modification enzyme independently, or fuse them together to form a fusion protein. In this case, they may be expressed in separate vectors or expressed by including them in a single vector.

[0205] In one specific example, the editor protein may consist of wild-type Cas9 and cytidine deaminase.

[0206] In another specific example, the editor protein may be composed of Cas9 nicase, cytidine deaminase, and UGI.

[0207] As another example, the editor protein of the present application may be a fusion protein formed by fusing a CRISPR enzyme and a base modification enzyme together. In this case, a linker may optionally be further included.

[0208] In one specific example, the editor protein may be a fusion protein in which wild-type Cas9 and deaminase are fused.

[0209] In another specific example, the editor protein may be composed of a fusion protein in which cytidine diaminese and UGI are fused, and Cas9 nicase.

[0210] In another specific example, the editor protein may be a fusion protein composed of Cas9 nicase, cytidine diaminese, and UGI.

[0211] 3) 가이드핵산

[0212] The gene manipulation composition disclosed by the present application further comprises a guide nucleic acid.

[0213] In one embodiment disclosed by the present application, the gene manipulation composition is a guide nucleic acid that targets a target sequence within the PERV gene.

[0214] The “guide nucleic acid” above refers to a nucleotide sequence capable of recognizing a target nucleic acid, gene, or chromosome and interacting with an editor protein. In this case, the guide nucleic acid can bind complementarily to a portion of the nucleotide sequence within the target sequence, gene, or chromosome. Additionally, a portion of the nucleotide sequence of the guide nucleic acid can interact with a portion of the amino acids of the editor protein to form a guide nucleic acid-editor protein complex (ribonucleoprotein, RNP).

[0215] The above guide nucleic acid can perform the function of inducing the guide nucleic acid-editor protein complex to be located in a target region of a target nucleic acid, gene, or chromosome.

[0216] The above guide nucleic acid may be in the form of DNA, RNA, or a DNA / RNA mixture.

[0217] The above guide nucleic acid may include one or more domains.

[0218] The above domain may be a functional domain such as a guide domain, a first complementary domain, a linking domain, a second complementary domain, a proximal domain, a tail domain, etc., but is not limited thereto.

[0219] “Guide RNA” (gRNA) refers to RNA capable of specifically targeting a gRNA-CRISPR enzyme complex, i.e., a CRISPR complex, for a target gene or nucleic acid. Furthermore, the gRNA refers to RNA specific to the target gene or nucleic acid, and can bind to the CRISPR enzyme to guide the CRISPR enzyme to the target gene or nucleic acid.

[0220] Guide RNA may include crRNA (CRISPR RNA) or / and tracrRNA (trans-activating crRNA). A form in which specific regions of the crRNA and the tracrRNA are fused may be referred to as sgRNA (single-chain guide RNA).

[0221] The above crRNA is a site that binds to the target sequence, and the above tracrRNA is involved in forming the following editor protein complex.

[0222] For example, the crRNA may include a guide domain and a first complementary domain, and the tracrRNA may include a second complementary domain, a proximal domain and optionally a tail domain.

[0223] The above guide domain is a domain containing a guide sequence capable of binding complementarily to a target sequence (guide nucleic acid binding sequence) on a target gene or nucleic acid, and can play a role in specific interaction with the target gene or nucleic acid.

[0224] The first complementary domain above is a nucleic acid sequence comprising a nucleic acid sequence complementary to the second complementary domain, and may have complementarity sufficient to form a double strand with the second complementary domain.

[0225] The above "linking domain" is a nucleic acid sequence that links two or more domains, and the linking domain can link two or more identical or different domains. The above linking domain can form covalent or non-covalent bonds with two or more domains, or can link two or more domains covalently or non-covalently.

[0226] The "second complementary domain" above is a nucleic acid sequence including a nucleic acid sequence complementary to the first complementary domain, and may have complementarity sufficient to form a double strand with the first complementary domain.

[0227] The above "proximal domain" may be a nucleic acid sequence located close to the second complementary domain.

[0228] The above "tail domain" may be a nucleic acid sequence located at one or more of the two ends of the guide nucleic acid.

[0229] For example, the composition of the present application may be a gRNA capable of targeting a target gene within the PERV gene.

[0230] As another example, the composition of the present application may be a gRNA capable of simultaneously targeting target genes present in each of two or more subtype gene sequences selected from PERV-A, PERV-B, and PERV-C.

[0231] The above gRNA may include a guide domain capable of forming partial or complete complementary binding with a guide nucleic acid binding sequence among the target sequences of the PERV gene.

[0232] The above gRNA may include a guide domain capable of forming partial or complete complementary binding with a guide nucleic acid binding sequence among the target sequences of the gag gene, pol gene and / or env gene.

[0233] The guide domain may be at least 70%, 75%, 80%, 85%, 90%, or 95% or more complementary to the guide nucleic acid binding sequence, or completely complementary.

[0234] The guide RNA may include a guide domain that binds complementarily to the guide nucleic acid binding target sequence and includes a sequence identical to the guide nucleic acid non-binding target sequence in which T is substituted with U.

[0235] Accordingly, the guide RNA comprises one or more nucleotide sequences of 5'-CAG-3', 5'-CAA-3', 5'-CGA-3', 5'-CUA-3', 5'-CCA-3', and 5'-UCA-3'.

[0236] In the present application, the portion of the guide RNA sequence that binds complementarily to the guide nucleic acid binding target sequence is the guide domain region.

[0237] The guide domain may include a nucleotide sequence complementary to the guide nucleic acid binding sequence among the target sequences of the PERV gene. In this case, the complementary nucleotide sequence may include 0 to 5, 0 to 4, 0 to 3, 0 to 2, or 0 to 1 mismatching.

[0238] The guide domain may include a nucleotide sequence complementary to the guide nucleic acid binding sequence among the target sequences of the gag gene. In this case, the complementary nucleotide sequence may include 0 to 5, 0 to 4, 0 to 3, 0 to 2, or 0 to 1 mismatching.

[0239] The guide domain may include a nucleotide sequence complementary to the guide nucleic acid binding sequence among the target sequences of the pol gene. In this case, the complementary nucleotide sequence may include 0 to 5, 0 to 4, 0 to 3, 0 to 2, or 0 to 1 mismatching.

[0240] The guide domain may include a nucleotide sequence complementary to the guide nucleic acid binding sequence among the target sequences of the env gene. In this case, the complementary nucleotide sequence may include 0 to 5, 0 to 4, 0 to 3, 0 to 2, or 0 to 1 mismatching.

[0241] The above gRNA may include one or more domains selected from the group consisting of a first complementary domain, a linking domain, a second complementary domain, a proximal domain, and a tail domain.

[0242] Among the above guide RNA sequences, domain regions other than the guide domain region contribute to forming a complex with the Cas protein.

[0243] In the present application, the guide nucleic acid non-binding target sequence within the gag gene, pol gene and / or env gene comprises PAM and a stop codonization target sequence. Additionally, when a base modification enzyme acts on the guide nucleic acid non-binding target sequence, some bases of the stop codonization target sequence are substituted (changed). At this time, a stop codon sequence within the target sequence may be generated by the substitution.

[0244] The above PAM sequence can provide selection criteria for the target sequence during gRNA design. Based on the PAM sequence, the target location is identified, and the target sequence is designed to include the region containing the stop codonization target sequence. In this case, the RNA sequence identical to the sequence where T is substituted with U in the guide nucleic acid non-binding target sequence is determined as the guide domain sequence.

[0245] Below, the guide domains of gRNA that can be used in one embodiment of the present application are summarized in [Table 4].

[0246] Name Target gene Direction gRNA (5' to 3', w / o PAM) SEQ ID NO PERV-gag-1_G gag + uucagguuaagaagggaccu SEQ ID NO: 66 PERV-gag-2_G gag + gcagacacucuucacagccg SEQ ID NO: 67 PERV-gag-3_G gag + ccagaagccucaguggccc SEQ ID NO: 68 PERV-gag-4_G gag + ucagagacuggaggguac SEQ ID NO: 69 PERV-gag-6_G gag - agccaugguuuaacccaugg SEQ ID NO: 70 PERV-gag-7_G gag - ucccaccgaggcgaguca SEQ ID NO: 71 PERV-gag-8_G gag - gucccaccgaggcgaguca SEQ ID NO: 72 PERV-gag-9_G gag + uccccgauccuggcucuug SEQ ID NO: 73 PERV-gag-10_G gag + gcgagagagauucuguuag SEQ ID NO: 74 PERV-gag-11_G gag + uccccaacgccucacggggu SEQ ID NO: 75 PERV-gag-12_G gag + ccaacgccucacgggguugg SEQ ID NO: 76 PERV-gag-13_G gag + guugcaaaaugagaugaca SEQ ID NO: 77 PERV-gag-14_G gag + uugcaaaaugagaugacau SEQ ID NO: 78 PERV-pol-1_G pol + ggagcaguuuccccaagccu SEQ ID NO: 79 PERV-pol-2_G pol + cccacagguuauucaacuga SEQ ID NO: 80 PERV-pol-3_G pol + acaguaccccuugaguagag SEQ ID NO: 81 PERV-pol-4_G pol + ggugcaggacauacaccca SEQ ID NO: 82 PERV-pol-5_G pol + ggcccagauuugcaggagag SEQ ID NO: 83 PERV-pol-6_G pol + cgggcagcgauggcugacgg SEQ ID NO: 84 PERV-pol-7_G most + gacaguacacccuagaagac SEQ ID NO: 85 PERV-pol-8_G most + agaccagucucugagacuc SEQ ID NO: 86 PERV-pol-9_G most + ccaguucucugagagacuccgg SEQ ID NO: 87 PERV-pol-10_G most + caguucucugagacuccgga SEQ ID NO: 88 PERV-pol-11_G most - ccaguuccguucaggcgggga SEQ ID NO: 89 PERV-pol-12_G most - accaguuccguucaggcgggg SEQ ID NO: 90 PERV-pol-13_G most - ugaccaguuccguucaggc SEQ ID NO: 91 PERV-pol-14_G most - cuccauucgaaggcaaaaag SEQ ID NO: 92 PERV-pol-15_G most - ccuccaugguccuaggguuu SEQ ID NO: 93 PERV-pol-16_G most - uccuccaugguccuaggguu SEQ ID NO: 94 PERV-pol-17_G most - cuucccagugagcgccugggg SEQ ID NO: 95 PERV-pol-18_G most - ccaguauuuuuuugccacca SEQ ID NO: 96 PERV-pol-19_G most - cuucaguugaauaaccugug SEQ ID NO: 97 PERV-pol-20_G most - uucuaagcaguccuguuugg SEQ ID NO: 98 PERV-pol-21_G most - uccuaggguguacugucguc SEQ ID NO: 99 PERV-pol-22_G most + agcgauggcugacggaggca SEQ ID NO: 100 PERV-pol-23_G most + gcucaaauuucuuuugaaca SEQ ID NO: 101 PERV-pol-24_G most + ucaagauauacaguccuggu SEQ ID NO: 102 PERV-pol-25_G most + caagccugggcagaaaccgc SEQ ID NO: 103 PERV-pol-26_G most + uguucaaagauuaauccaac SEQ ID NO: 104 PERV-pol-27_G pol + guucaaagauuaauccaaca SEQ ID NO: 105 PERV-pol-28_G pol + aaacaagugagagaguuuuu SEQ ID NO: 106 PERV-pol-29_G pol + aacaagugagagaguuuuug SEQ ID NO: 107 PERV-pol-30_G pol + cccaaacccuaggaccaugg SEQ ID NO: 108 PERV-pol-31_G pol + caacuauugauugaggagac SEQ ID NO: 109 PERV-pol-32_G pol + agcgcaaaaggcugagcuca SEQ ID NO: 110 PERV-pol-33_G pol + caagcuuugcggcuggccga SEQ ID NO: 111 PERV-pol-34_G pol + uccgagauuuggaauaccua SEQ ID NO: 112 PERV-env-1_G env + aacaggaaaauauucaaaag SEQ ID NO: 113 PERV-env-2_G env + ugaacaggggcccccggccc SEQ ID NO: 114 PERV-env-3_G env + cagcagcuagagaaaggacu SEQ ID NO: 115 PERV-env-4_G env + accaggggugguuugaagga SEQ ID NO: 116 PERV-env-5_G env - ccagcuuaacgugggaugca SEQ ID NO: 117 PERV-env-6_G env - uuuccagucuccaucguugg SEQ ID NO: 118 PERV-env-7_G env - ccauuuccagucuccaucgu SEQ ID NO: 119 PERV-env-8_G env - gcccaccaccuguuauaacc SEQ ID NO: 120 PERV-env-9_G env - accauccuucaaaccacccc SEQ ID NO: 121 PERV-env-10_G env + acucgagguguugcuccuag SEQ ID NO: 122 PERV-env-11_G env + ccgaguguacuaccauccug SEQ ID NO: 123 PERV-env-12_G env + uaccaaggccuucugagcca SEQ ID NO: 124 PERV-env-13_G env - gucuauaaggcguuuacuac SEQ ID NO: 125 PERV-env-14_G env - gaccaugacacagaaaucuu SEQ ID NO: 126 PERV-env-15_G env - accauccuucaaaccacccc SEQ ID NO: 127 PERV-env-16_G env - acccacucguucucuaacaa SEQ ID NO: 128 PERV-env-17_G env - cgucagagcagaaagcaggg SEQ ID NO: 129 PERV-env-18_G env - uccuaugcauguccccuucc SEQ ID NO: 130

[0247] 4) Forms of compositions for genetic engineering

[0248] The gene manipulation composition of the present application may include a guide nucleic acid and an editor protein.

[0249] A composition for genetic engineering is,

[0250] (a) a guide nucleic acid capable of targeting a target sequence within a target nucleic acid sequence or a nucleic acid sequence encoding the same; and

[0251] (b) one or more editor proteins or nucleic acid sequences encoding them;

[0252] It may include.

[0253] The above target nucleic acid may be the full length or a partial nucleic acid sequence of the PERV gene.

[0254] At this time, the above PERV gene may include the gag gene, the pol gene, and / or the env gene. The description regarding the above PERV gene is as described above.

[0255] The above target nucleic acid may be a gag gene.

[0256] The above target nucleic acid may be the pol gene.

[0257] The above target nucleic acid may be an env gene.

[0258] The above target nucleic acids may be two selected genes among the gag gene, pol gene, and env gene.

[0259] The above target nucleic acids may be the gag gene, pol gene, and env gene.

[0260] The above description regarding the target sequence is as described above.

[0261] The above target sequence may include a specific sequence.

[0262] The specific sequence mentioned above may be a nucleotide sequence of 5'-CAG-3'.

[0263] The specific sequence mentioned above may be a nucleotide sequence of 5'-CAA-3'.

[0264] The specific sequence above may be a nucleotide sequence of 5'-CGA-3'.

[0265] The specific sequence mentioned above may be a nucleotide sequence of 5'-CTA-3'.

[0266] The specific sequence mentioned above may be a nucleotide sequence of 5'-CCA-3'.

[0267] The specific sequence mentioned above may be a nucleotide sequence of 5'-TCA-3'.

[0268] In one embodiment disclosed by the present application, a composition for genetic engineering may include gRNA, a CRISPR enzyme, and a base modification enzyme.

[0269] A composition for genetic engineering is

[0270] (a) a gRNA capable of targeting a target sequence within a target nucleic acid sequence or a nucleic acid sequence encoding the same;

[0271] (b) one or more CRISPR enzymes or nucleic acid sequences encoding the same; and

[0272] (C) One or more base modification enzymes or nucleic acid sequences encoding them;

[0273] It may include.

[0274] The above target nucleic acid may be the full length or a partial nucleic acid sequence of the PERV gene.

[0275] At this time, the above PERV gene may include the gag gene, the pol gene, and / or the env gene. The description regarding the above PERV gene is as described above.

[0276] The above target nucleic acid may be a gag gene.

[0277] The above target nucleic acid may be the pol gene.

[0278] The above target nucleic acid may be an env gene.

[0279] The above target nucleic acids may be two selected genes among the gag gene, pol gene, and env gene.

[0280] The above target nucleic acids may be the gag gene, pol gene, and env gene.

[0281] The above description regarding the target sequence is as described above.

[0282] The above target sequence may include a specific sequence.

[0283] The specific sequence mentioned above may be a nucleotide sequence of 5'-CAG-3'.

[0284] The specific sequence mentioned above may be a nucleotide sequence of 5'-CAA-3'.

[0285] The specific sequence above may be a nucleotide sequence of 5'-CGA-3'.

[0286] The specific sequence mentioned above may be a nucleotide sequence of 5'-CTA-3'.

[0287] The specific sequence mentioned above may be a nucleotide sequence of 5'-CCA-3'.

[0288] The specific sequence mentioned above may be a nucleotide sequence of 5'-TCA-3'.

[0289] The above description regarding the CRISPR enzyme is as described above.

[0290] The above CRISPR enzyme may be Cas9 nicase.

[0291] The description regarding the base modification enzyme above is as described above.

[0292] The above base modifying enzyme may be a deaminase.

[0293] The above deaminase may be cytidine deaminase.

[0294] The above CRISPR enzyme and the above base modification enzyme may be a fusion protein fused with each other.

[0295] The above genetic engineering composition may further include a DNA glycosylase inhibitor.

[0296] The above description regarding DNA glycosylase inhibitors is as described above.

[0297] The above DNA glycosylase inhibitor may be a uracil glycosylase inhibitor.

[0298] The above CRISPR enzyme, base modification enzyme, and DNA glycosylase inhibitor may be included in the gene manipulation composition in the form of a fusion protein in which two or more of these are fused together.

[0299] The description regarding the guide nucleic acid and editor protein above is as described above.

[0300] The guide nucleic acid, editor protein, or guide nucleic acid-editor protein complex included in the gene manipulation composition disclosed by the present application can be delivered or introduced into a cell in various forms.

[0301] The above guide nucleic acid and editor protein can be delivered or introduced into the target in the form of a nucleic acid-protein mixture.

[0302] The above guide nucleic acid and editor protein can be delivered or introduced into the target in the form of a guide nucleic acid-editor protein complex.

[0303] For example, the guide nucleic acid may be in the form of DNA, RNA, or a mixture thereof. The editor protein may be in the form of a peptide, polypeptide, or protein.

[0304] For example, guide nucleic acid and editor protein can be delivered or introduced into a target in the form of a guide nucleic acid-editor protein complex, i.e., a ribonucleoprotein (RNP), where the guide nucleic acid in RNA form and the editor protein in protein form are introduced.

[0305] The above-mentioned composition for genetic manipulation may be in a form included in a vector or a non-vector.

[0306] At this time, the vector may be composed of a nucleic acid sequence encoding the guide nucleic acid or / and the CRISPR enzyme or / and the base modification enzyme, either simultaneously or individually.

[0307] The vector can be a viral vector or a recombinant viral vector.

[0308] The above virus may be a DNA virus or an RNA virus.

[0309] At this time, the DNA virus may be a double-stranded DNA (dsDNA) virus or a single-stranded DNA (ssDNA) virus.

[0310] In this case, the RNA virus may be a single-stranded RNA (ssRNA) virus.

[0311] The above viruses may be retroviruses, lentiviruses, adenoviruses, adeno-associated viruses (AAVs), vacciniaviruses, poxviruses, or herpes simplex viruses, but are not limited thereto.

[0312] The above vector may include one or more regulation / control components.

[0313] At this time, the regulation / control component may include a promotor, enhancer, intron, polyadenylation signal, Kozak consensus sequence, internal ribosome entry site (IRES), splice acceptor and / or 2A sequence.

[0314] The above promoter may use a suitable promoter depending on the control region (i.e., a nucleic acid sequence encoding a guide nucleic acid or an editor protein).

[0315] For example, a useful promoter for a guide nucleic acid may be the H1, EF-1a, tRNA, or U6 promoter. For example, a useful promoter for an editor protein may be the CMV, EF-1a, EFS, MSCV, PGK, or CAG promoter.

[0316] The above vector may include one or more additional domains for separation and purification.

[0317] At this time, the one or more additional domains may be tags or reporter genes for the isolation and purification of proteins (including peptides).

[0318] The above tags include histidine (His) tag, V5 tag, FLAG tag, influenza hemagglutinin (HA) tag, Myc tag, VSV-G tag and thioredoxin (Trx) tag, etc., and the reporter gene includes, but is not limited to, autofluorescent proteins including glutathione-S-transferase (GST), horseradish peroxidase (HRP), chloramphenicol acetyltransferase (CAT), beta-galactosidase, beta-glucuronidase, luciferase, green fluorescent protein (GFP), HcRed, DsRed, cyan fluorescent protein (CFP), yellow fluorescent protein (YFP) and blue fluorescent protein (BFP).

[0319] The above non-vector may be naked DNA, a DNA complex, mRNA, or a mixture thereof.

[0320] The above non-vector may be delivered or introduced into the target by electroporation, gene gun, ultrasonic perforation, magnetofection, transient cell compression or squeezing (e.g., as described in the literature [Lee, et al, (2012) Nano Lett., 12, 6322-6327]), lipid-mediated transfection, dendrimers, nanoparticles, calcium phosphate, silica, silicate (Ormosyl), or a combination thereof.

[0321] For example, delivery via electroporation can be performed by mixing a cell and a nucleic acid sequence encoding a guide nucleic acid and / or an editor protein within a cartridge, chamber, or cuvette, and applying an electrical stimulus of a defined duration and amplitude.

[0322] As another example, non-vectors can be delivered using nanoparticles. The nanoparticles may be inorganic nanoparticles (e.g., magnetic nanoparticles, silica, etc.) or organic nanoparticles (e.g., lipids coated with polyethylene glycol (PEG)). The outer surface of the nanoparticles may be conjugated with a positively charged polymer (e.g., polyethyleneimine, polylysine, polycerin, etc.) that enables attachment.

[0323] In any specific example, it can be delivered using a lipid envelope.

[0324] As an optional specific example, it can be delivered using exosomes. Exosomes are endogenous nano-vesicles that transport proteins and RNA, capable of delivering RNA to the brain and other target organs.

[0325] In any specific example, delivery can be made using liposomes. A liposome is a spherical vesicular structure composed of a single or multiple lamellar lipid bilayer surrounding an inner aqueous compartment and a relatively impermeable outer lipophilic phospholipid bilayer. Although liposomes can be made from several different types of lipids; phospholipids are most commonly used to produce liposomes as drug carriers.

[0326] In addition, the composition for the delivery of non-vectors may include several other additives.

[0327] 4-1) Components for Knock-In to the Pig Genome

[0328] The gene manipulation composition of the present application can be knocked into the pig genome to achieve continuous inactivation of PERV in the pig genome. When the gene manipulation composition is knocked into the genome, the likelihood of permanently inactivating PERV in a multi-copy state, rather than temporarily inactivating it, can be increased. Furthermore, since the gene manipulation composition of the present application uses a CRISPR / Cas system, it not only inhibits the transcription or / and translation of the target gene of PERV but also generates a stop codon sequence within the target sequence of the said target gene, thereby achieving target-specific and highly efficient PERV inactivation.

[0329] To this end, the vector may include one or more transfer factors.

[0330] The above-mentioned transfer factor or a vector containing it may be located within a safe harbor.

[0331] For example, the above safe harbor may be AAVS1, ROSA26, etc.

[0332] The above safe harbor allows the expression of the foreign gene or the vector containing it to continue without causing side effects even when the foreign gene or the vector containing it is inserted or knocked into a specific part of the pig genome.

[0333] The above-mentioned transposable factor piggyBac Transposable factor or Sleeping Beauty It can be a metastasis factor.

[0334] .

[0335] The above piggyBac Transposable elements may include inverted terminal repeat sequences (ITRs) at both ends.

[0336] The above piggyBac Transposable factors are enzymes that mediate translocation. piggyBacIt may contain transposase.

[0337] The above piggyBac Transposable elements can be inserted into the genome by recognizing specific nucleotide sequences.

[0338] At this time, the specific nucleotide sequence may be a target insertion site, and the target insertion site may be TTAA.

[0339] In this case, the genome can be the genome of animal cells, including pig cells, human cells, mouse cells, and rat cells.

[0340] The above piggyBac Transposable elements may include external genes or nucleic acid sequences.

[0341] The above piggyBac Transposable elements may include an external gene or nucleic acid sequence between the two terminal ITRs.

[0342] The above external gene or nucleic acid sequence may be the gene or nucleic acid sequence to be translocated.

[0343] The above external gene or nucleic acid sequence may be a guide nucleic acid and / or an editor protein.

[0344] At this time, the above external gene is piggyBac It can be inserted into the genome by transposable elements.

[0345] For example, the above-mentioned transposable factor piggyBac In the case of a transfer factor, the above vector system can be configured as follows. piggyBac The transposable element may include a nucleic acid sequence encoding a guide nucleic acid and an editor protein between the ITRs at both ends. Or the above piggyBac The transposable element may include a nucleic acid sequence encoding a guide nucleic acid or an editor protein between the two terminal ITRs.

[0346] The above Sleeping BeautyTransposable elements may include direct repeats (DRs) at both ends.

[0347] The above Sleeping Beauty Transposable factors may contain ITRs at both ends.

[0348] At this time, the above ITR may include DR.

[0349] The above Sleeping Beauty Transposable factors are enzymes that mediate translocation. Sleeping Beauty It may contain transposase.

[0350] The above Sleeping Beauty Transposable elements can be inserted into the genome by recognizing specific nucleotide sequences.

[0351] At this time, the specific nucleotide sequence may be a target insertion site, and the target insertion site may be a TA.

[0352] In this case, the genome can be the genome of animal cells, including pig cells, human cells, mouse cells, and rat cells.

[0353] The above Sleeping Beauty Transposable elements may include external genes or nucleic acid sequences.

[0354] The above Sleeping Beauty Transposable elements may include an external gene or nucleic acid sequence between the two terminal ITRs.

[0355] The above external gene or nucleic acid sequence may be the gene or nucleic acid sequence to be translocated.

[0356] The above external gene or nucleic acid sequence may be a guide nucleic acid and / or an editor protein.

[0357] At this time, the above external gene is Sleeping Beauty It can be inserted into the genome by transposable elements.

[0358] For example, the above-mentioned transposable factor Sleeping Beauty In the case of a transfer factor, the above vector system can be configured as follows. Sleeping Beauty The transposable element may include a nucleic acid sequence encoding a guide nucleic acid and an editor protein between the ITRs at both ends. Or the above Sleeping Beauty The transposable element may include a nucleic acid sequence encoding a guide nucleic acid or an editor protein between the two terminal ITRs.

[0359] In the embodiment of the present application, it can be confirmed through the results of FIG. 3 that the genetic engineering composition was knocked into the pig genome. Furthermore, through the results of FIG. 4 and FIG. 5, it can be confirmed that the genetic engineering composition generated a stop codon in the target sequence of the PERV gene.

[0360] IV. PERV Inactivation Method

[0361] Another aspect disclosed by the present application relates to a method for inactivating PERV using the above-described genetic engineering composition. The description of the above-described genetic engineering composition is as described above.

[0362] For example, the above method is,

[0363] The method includes the step of introducing a genetic engineering composition into pig cells; and

[0364] At this time, the above genetic engineering composition is,

[0365] (a) a guide nucleic acid capable of targeting a target sequence within a target nucleic acid sequence or a nucleic acid sequence encoding the same; and

[0366] (b) one or more editor proteins selected from the group consisting of Cas9 proteins derived from Streptococcus pyogenes, Cas9 proteins derived from Campylobacter jejuni, Cas9 proteins derived from Streptococcus thermophiles, Cas9 proteins derived from Staphylococcus aureus, Cas9 proteins derived from Neisseria meningitidis, Staphylococcus auricularis Cas9 (SauriCas9), and Cpf1 proteins, or nucleic acid sequences encoding the same;

[0367] It may include.

[0368] As another example, the above method is,

[0369] The method includes the step of introducing a genetic engineering composition into pig cells; and

[0370] At this time, the above genetic engineering composition is,

[0371] (a) a guide nucleic acid capable of targeting a target sequence within a target nucleic acid sequence or a nucleic acid sequence encoding the same;

[0372] (b) one or more editor proteins selected from the group consisting of Cas9 proteins derived from Streptococcus pyogenes, Cas9 proteins derived from Campylobacter jejuni, Cas9 proteins derived from Streptococcus thermophiles, Cas9 proteins derived from Staphylococcus aureus, Cas9 proteins derived from Neisseria meningitidis, Staphylococcus auricularis Cas9 (SauriCas9), and Cpf1 proteins, or nucleic acid sequences encoding the same; and

[0373] (c) one or more deaminases or nucleic acid sequences encoding them;

[0374] It may include.

[0375] The above introduction can be performed using one or more methods selected from electroporation, liposomes, plasmids, viral vectors, nanoparticles, and PTD (Protein translocation domain) fusion protein methods.

[0376] The above plasmid may be a vector containing a transposable element for porcine genome knock-in.

[0377] The description regarding the vector including the aforementioned transfer factor is as described above.

[0378] The above virus vector may be one or more selected from the group consisting of retroviruses, lentiviruses, adenoviruses, adeno-associated viruses (AAVs), vacciniaviruses, poxviruses, and herpes simplex viruses.

[0379] In another embodiment, the above-mentioned manipulation composition may be delivered or introduced into the target as a non-vector.

[0380] The explanation regarding the above non-vector is as described above.

[0381] The above target may be a pig or a pig cell.

[0382] At this time, the pig cells may include cells from a primary pig culture or commercial pig cell lines.

[0383] In a specific example, the method may be a method for producing pig cells comprising the step of introducing a genetic engineering composition capable of artificially manipulating the gene of PERV into pig cells.

[0384] The above pig cells may be pig cells containing the PERV gene.

[0385] The above pig cells may be pig cells containing the full or partial nucleic acid sequence of the PERV gene.

[0386] At this time, the full length or part of the nucleic acid sequence of the above PERV gene may be present in the genome of pig cells.

[0387] At this time, the full length or part of the nucleic acid sequence of the above PERV gene may be present in pig cells.

[0388] The above target nucleic acid may be the full length or a partial nucleic acid sequence of the PERV gene.

[0389] At this time, the above PERV gene may include the gag gene, the pol gene, and / or the env gene. The description regarding the above PERV gene is as described above.

[0390] The above target nucleic acid may be a gag gene.

[0391] The above target nucleic acid may be the pol gene.

[0392] The above target nucleic acid may be an env gene.

[0393] The above target nucleic acids may be two selected genes among the gag gene, pol gene, and env gene.

[0394] The above target nucleic acids may be the gag gene, pol gene, and env gene.

[0395] In some embodiments, the method comprises the steps of extracting cells or a cell population from a pig and modifying the cells or a cell population. Cell culture may take place in vitro at any stage. The modified cells or a cell population may be reintroduced into a pig or a human, and furthermore, the nuclei or genomes extracted from the modified cells or a cell population may be transplanted into pig cells.

[0396] Method to determine whether a composition has been introduced into a target

[0397] The above method is,

[0398] The step of confirming whether the above-mentioned gene manipulation composition has been introduced may be optionally further included.

[0399] The step of verifying whether the above-mentioned introduction is performed using known technology.

[0400] For example, the above-described technology may include a method for confirming transformation or a method for screening transduction.

[0401] The above selection method may be a method using a selectable marker.

[0402] The above screening markers may include antibiotic genes, fluorescent proteins, etc.

[0403] For example, the above antibiotic gene may be ampicillin, neomycin, kanamycin, hygromycin, gentamicin, puromycin, etc.

[0404] For example, the fluorescent protein may be a green fluorescent protein (GFP), a yellow fluorescent protein (YFP), a red fluorescent protein (RFP), etc.

[0405] When using the above-mentioned screening marker, the screening marker may be included in the above-mentioned composition.

[0406] A screening marker can be used as an indicator of whether the above composition has been introduced into the target. An antibiotic resistance gene is used as a screening marker, and the above composition is inserted together with it; if colonies are formed when cells are cultured in a medium containing antibiotics, it can be determined that the above composition has been introduced.

[0407] For example, if the target to which the above composition is introduced is a cell and the selection marker is an antibiotic gene, selection can be performed as follows. If colonies are formed by culturing the cell in a medium containing an antibiotic, it can be determined that the above composition has been introduced into the cell.

[0408] Using the method described above, pig cells in which PERV is inactivated on the pig genome can be selected and obtained.

[0409] V. Animal cells, animals, and animal organs inactivated with PERV

[0410] Another aspect disclosed by the present application relates to pig cells, pigs, or pig organs that have been artificially manipulated so that PERV is inactivated using the above method.

[0411] 1) Artificially manipulated pig cells

[0412] One example concerns artificially manipulated pig cells.

[0413] "Manipulated porcine cell" (or "engineered porcine cell") refers to a pig cell that has been artificially manipulated rather than in its natural state.

[0414] Manipulated pig cells may be pig cells produced by genetic engineering.

[0415] The engineered pig cells may be pig cells containing artificially engineered porcine endogenous retrovirus (PERV) genes.

[0416] The engineered pig cells may be pig cells in which PERV gene transfer has been inhibited.

[0417] The above PERV gene transfer may be a localized transfer on the genome within the engineered pig cells.

[0418] The above PERV gene transfer may be a transfer into the genome of adjacent cells to the engineered pig cells, that is, neighboring cells that are engineered or not engineered.

[0419] At this time, the adjacent cell may be an animal cell including pig cells, human cells, mouse cells, and rat cells.

[0420] The engineered pig cells may be pig cells in which the production of the protein encoded by the PERV gene is inhibited or suppressed.

[0421] The engineered pig cells may be pig cells in which the production of the protein encoded by the gag gene is inhibited or suppressed.

[0422] The engineered pig cells may be pig cells in which the production of a protein encoded by the pol gene is inhibited or suppressed.

[0423] The engineered pig cells may be pig cells in which the production of the protein encoded by the env gene is inhibited or suppressed.

[0424] The engineered pig cells may be pig cells in which the production of two or more proteins encoded by the gag gene, pol gene and env gene is inhibited or suppressed.

[0425] In one embodiment disclosed by the present specification, the engineered pig cell may be a pig cell comprising one or more of an artificially engineered gag gene, an artificially engineered pol gene, and an artificially engineered env gene.

[0426] The above artificially manipulated gag gene, artificially manipulated pol gene and artificially manipulated env gene may be artificially manipulated to include a specific sequence.

[0427] At this time, the specific sequence mentioned above may be a stop codon.

[0428] At this time, the specific sequence may be 5'-TAG-3', 5'-TAA-3' and / or 5'-TGA-3'.

[0429] The artificially manipulated gag gene mentioned above may be a gene containing two or more stop codons.

[0430] The artificially manipulated pol gene mentioned above may be a gene containing two or more stop codons.

[0431] The artificially manipulated env gene mentioned above may be a gene containing two or more stop codons.

[0432] The above two or more stop codons may include a first stop codon and one or more additional stop codons.

[0433] In this case, the “first stop codon” refers to a stop codon located at the 3’ end of a natural gag gene, pol gene and / or env gene.

[0434] The first termination codon mentioned above may be one of 5'-TAG-3', 5'-TAA-3' and 5'-TGA-3'.

[0435] At this time, the “additional stop codon” refers to a stop codon excluding the first stop codon within the nucleic acid sequence of the artificially manipulated gag gene, pol gene and / or env gene, and this may be an artificially generated stop codon that does not exist within the nucleic acid sequence of the gag gene, pol gene and / or env gene in its natural state.

[0436] The above additional stop codon may have the same or different nucleotide sequence as the first stop codon.

[0437] The above additional termination codon may be 5'-TAG-3', 5'-TAA-3' and / or 5'-TGA-3'.

[0438] For example, the above additional stop codon may be located at or adjacent to the 5' end of the nucleic acid sequence of the gag gene, pol gene and / or env gene.

[0439] As another example, the above additional stop codon may be located within the nucleic acid sequence of the gag gene, pol gene and / or env gene.

[0440] As another example, the above additional stop codon may be located adjacent to the 3' end of the gag gene, pol gene and / or env gene.

[0441] One or more of the above additional stop codons may be located within a continuous nucleotide sequence of 1 bp to 100 bp adjacent to the 5' end and / or 3' end of the PAM (proto-spacer-adjacent Motif) sequence within the nucleic acid sequence of the gag gene, pol gene and / or env gene.

[0442] In other words, the above-mentioned manipulated pig cells do not only possess stop codons that are naturally present in the genome, that is, naturally existing, but also include artificially generated stop codons. More specifically, the above-mentioned pig cells contain stop codons that are naturally present in the gag, pol, and env genes of PERV, respectively, and additionally include artificially generated stop codons in the gag, pol, and env genes, respectively, thereby inactivating PERV.

[0443] As a specific example,

[0444] The artificially manipulated gag gene may include one or more additional stop codons within the nucleic acid sequence of the gag gene in addition to the first stop codon located at the 3' end of the nucleic acid sequence of the wild-type gag gene.

[0445] The artificially manipulated pol gene may include one or more additional stop codons within the nucleic acid sequence of the pol gene in addition to the first stop codon located at the 3' end of the nucleic acid sequence of the wild-type pol gene.

[0446] The artificially manipulated env gene may include one or more additional stop codons within the nucleic acid sequence of the env gene in addition to the first stop codon located at the 3' end of the nucleic acid sequence of the wild-type env gene.

[0447] In this application, more specific examples of pig cells comprising one or more artificially engineered genes are listed:

[0448] For example, the above-mentioned engineered pig cell is a pig cell containing one artificially engineered gene. The above-mentioned artificially engineered gene is one of the artificially engineered gag gene, the artificially engineered pol gene, and the artificially engineered env gene. In this case, the above-mentioned artificially engineered gene includes a first stop codon and one or more additional stop codons, and the additional stop codon may be located within a continuous nucleotide sequence of 1 bp to 100 bp located adjacent to the 5' end and / or 3' end of the 5'-NGG-3' (N is A, T, C, or G) PAM sequence of the one or more artificially engineered genes.

[0449] As another example, the above-mentioned engineered pig cell is a pig cell containing two artificially engineered genes. The two artificially engineered genes are two of the artificially engineered gag gene, the artificially engineered pol gene, and the artificially engineered env gene. In this case, each of the two artificially engineered genes includes a first stop codon and one or more additional stop codons, and the additional stop codon may be located within a continuous nucleotide sequence of 1 bp to 100 bp adjacent to the 5' end and / or 3' end of the 5'-NGG-3' (N is A, T, C, or G) PAM sequence of the one or more artificially engineered genes.

[0450] As another example, the above-mentioned engineered pig cell is a pig cell containing three artificially engineered genes. The three artificially engineered genes are the artificially engineered gag gene, the artificially engineered pol gene, and the artificially engineered env gene. In this case, each of the three artificially engineered genes includes a first stop codon and one or more additional stop codons, and the additional stop codon may be located within a continuous nucleotide sequence of 1 bp to 100 bp adjacent to the 5' end and / or 3' end of the 5'-NGG-3' (N is A, T, C, or G) PAM sequence of the one or more artificially engineered genes.

[0451] In any embodiment, the pig cells are,

[0452] A porcine endogenous retrovirus (PERV) containing in its genome one or more genes selected from the gag, pol, and env genes inactivated, and

[0453] As a pig cell containing at least two stop codons within the above-mentioned inactivated gene,

[0454] The above stop codon is one or more nucleotide sequences selected from 5'-TAG-3', 5'-TAA-3', and 5'-TGA-3', and

[0455] The above-mentioned inactivated PERV exists as multiple copies within the genome, and

[0456] The expression level of PERV may have decreased by more than 50% compared to before inactivation.

[0457] 2) Artificially manipulated transgenic pigs

[0458] One aspect disclosed by the present application relates to a transgenic pig.

[0459] The above-mentioned transgenic pig may be manufactured using engineered pig cells.

[0460] The description regarding the manipulated pig cells above is as described above.

[0461] As an example, the invention relates to a method for producing a transgenic pig by transplanting a nucleus extracted from a manipulated pig cell into an enucleated oocyte to produce offspring, and to a transgenic pig produced thereby.

[0462] The above-mentioned transgenic pig may be a pig in which the full or partial nucleic acid sequence of the PERV gene, which was artificially manipulated within the genome, is present.

[0463] The above description regarding the artificially manipulated PERV gene is as described above.

[0464] In one embodiment, to produce a transgenic pig, somatic cell nuclear transfer (SCNT) can be used with engineered pig cells.

[0465] The method for producing transgenic pigs is,

[0466] (a) A step of producing engineered pig cells, i.e., nuclear donor cells, by culturing somatic cells or stem cells isolated from pig tissue and introducing a composition for genetic engineering;

[0467] (b) a step of producing an enucleated oocyte by removing the nucleus from a pig oocyte;

[0468] (c) a step of microinjecting the nucleus of the engineered pig cell from step (a), i.e., the nuclear donor cell, into the enucleated oocyte from step (b) above and fusing them;

[0469] (d) a step of activating the fused oocyte in step (c) above; and

[0470] (e) A step of implanting the activated egg into the fallopian tube of the surrogate mother.

[0471] It may include.

[0472] The conventional technical details regarding each step can be understood by referring to conventional methods for manufacturing cloned animals using somatic cell nuclear transfer technology known in the art.

[0473] 3) Transgenic pig organs

[0474] Additionally, one aspect disclosed by this specification relates to a transgenic pig organ.

[0475] The above-mentioned transgenic pig organ may be an organ obtained from a transgenic pig.

[0476] The explanation regarding the Sanji transgenic pig is as described above.

[0477] The above-mentioned genetically modified pig organs may be any organ suitable for transplantation, such as the heart, liver, kidney, and small intestine.

[0478] At this time, the transplant may be a homograft or a heterograft.

[0479] Artificial manipulation or modification of the PERV gene using the genetic engineering composition disclosed in this application can solve the problems of cytotoxicity and apoptosis caused by genome rearrangement, etc., that occur during the knockout of multiple copies of a gene using the existing CRISPR-Cas system, and can effectively and safely inactivate the target gene of the targeted multiple copies. In addition, transgenic pigs produced using the engineered pig cells disclosed in this specification can be usefully utilized for xenotransplantation treatment.

[0480] Form for carrying out the invention

[0481] The present invention will be explained in more detail below through examples.

[0482] These examples are provided solely to illustrate the invention more specifically, and it will be obvious to those skilled in the art that the scope of the invention is not limited by these examples.

[0483] Experimental Methods and Results

[0484] 1. gRNA Design

[0485] gRNA was designed as follows using http: / / www.rgenome.net / be-designer / .

[0486] Specifically, 1) among the gRNA sequences that may exist in the gag, pol, and env genes of PERV, only those gRNAs capable of inducing a stop codon by C to T base editing were selected, and 2) each gRNA sequence was analyzed to determine whether it could simultaneously target PERV-A, PERV-B, and PERV-C, thereby selecting only gRNAs capable of simultaneously targeting PERV-A, PERV-B, and PERV-C with a single gRNA. In this example, among the selected gRNAs, the gRNA at a position close to the start codon was finally selected and used (Table 5).

[0487]

[0488] In this embodiment, guide RNAs targeting SEQ ID NO: 132 and SEQ ID NO: 139, respectively, were designed.

[0489] 2. Vector Creation (All-in-one PiggyBac vector cloning)

[0490] The piggybac vector (#20960) and Target-AID vector (#79620; pcDNA3.1_pCMV-nCas-PmCDA1-ugi pH1-gRNA(HPRT)) were purchased from Addgene. sgRNAs targeting PERV-gag and PERV-pol were synthesized with U6 promoter sequences (U6-sgGag and U6-sgPol). An all-in-one PiggyBac vector was constructed using these vectors (Fig. 2). The primer sequences used for vector construction are as follows (Table 6):

[0491] The above vector was designed to include all sequences encoding guide RNAs containing the guide domain sequences of SEQ ID NO. 66 and SEQ ID NO. 81, respectively.

[0492] Gene range Direction Primer Sequence (5' to 3') Length, Temp. SEQ. ID No. gag 1-529 1 st Forward ctggtggtctcctactgtcg 20bp, 57-58℃ SEQ ID NO: 157 1 st Reverse ctccaagagccaggattcgg 20bp, 59℃ SEQ ID NO: 158 2-285 2 nd Forward gtcttgtgcgtccttgtcta 20bp, 54℃ SEQ ID NO: 159 2 nd Reverse cgtaaggatatagggctcct 20bp, 54-55℃ SEQ ID NO: 160 pol 1-495 1 st Forward ccatcactgtgttgaccctc 20bp, 56-57℃ SEQ ID NO: 161 1 st Reverse ggtgtaatctcaggcagaag 20bp, 54-55℃ SEQ ID NO: 162 2-295 2 nd Forward tatacagtcctggttggagc 20bp, 54-56℃ SEQ ID NO: 163 2 nd Reverse attgacctctctcaagtcct 20bp, 54-55℃ SEQ ID NO: 164

[0493] 1 st In-fusion cloning: PB-MluI-NotI cloning

[0494] 2 nd Restriction enzyme cloning: PB-MluI-NotI & MluI-CMV-nCas9-PmCDA1-UGI-NeoR / KanR-pA-NotI

[0495] ( vector size: 4352bp, insert size: 7199bp)

[0496] 3 rd In-fusion cloning: PB-CMV-nCas9-PmCDA1-UGI-NeoR / KanR-pA NotI + U6-sgGag + U6-sgPol

[0497] At this time, 3 rd The abbreviations listed in In-fusion cloning refer to the following:

[0498] nCas9 (nickase Cas9), UGI (uracil-DNA glycosylase inhibitor), PmCDA1 (cytidine deaminase 1)

[0499] NeoR (neomycin resistance), KanR (kanamycin resistance), pA (poly A).

[0500] 3. Cell transfection

[0501] The PWG #8 cell line (Passage: 3) to be used for transfection was cultured in the following medium composition:

[0502] Dulbecco's modified Eangel medium (DMEM) (Gibco, Carlsbad, California, USA)

[0503] 1% P / S, 10% Fetal bovine serum (FBS) (Gibco)

[0504] 100 mM β-Mercaptoethanol (β-ME) (Sigma)

[0505] 1% Non-essential amino acids (NEAA) (Gibco)

[0506] Cultured porcine fibroblast cell lines (PWG cells) were prepared by washing with PBS and treating with trypsin. The prepared 3x10 5 500 ng of the All-in-one PiggyBac vector prepared in Experiment Method 2 above was transfected into PWG cells using a Neon electroporator (ThermoFisher).

[0507] After transfection, the transduced PWG cells were cultured in clean medium and replaced with clean medium after 4 hours. Two days later, Neomycin (2 μg / mL) was administered for 10 days. Subsequently, colonies derived from single cells were selected for the experiment. Since the all-in-one PiggyBac vector contains the antibiotic resistance gene NeoR as a selection marker, the cells that survived when treated with neomycin were transgene-transduced cells.

[0508] 4. Verification of transgene integration (Identification of transgene integration)

[0509] The following experiment was conducted to determine whether the corresponding transgene was introduced (integrated) into the genome of cells that survived upon neomycin treatment.

[0510] Genomic DNA from cells was extracted using the DNeasy Blood & Tissue Kit (Qiagen, Cat No. / ID: 69506), and PCR was performed using the primers indicated by the arrows in Fig. 2. The samples were then loaded onto an agarose gel to visualize the bands (Fig. 3). The primers used are as follows (Table 7):

[0511] Name Primer Sequence (5' to 3') SEQ. ID No. integration_Forward CCTCGTGCTTTACGGTATCG SEQ ID NO: 165 integration_Reverse ATGCTCAAGGGGCTTCATGA SEQ ID NO: 166

[0512] In Figure 3, Colonies #1 and #3 represent single-cell derived colonies obtained after Neomycin selection, respectively. Looking at Figure 3, the band corresponding to the transgene is clearly observed in both Colonies #1 and #3.

[0513] In other words, through the results of Figure 3, it was confirmed that the transgene introduced into the cell through transfection was integrated into the cell's genome.

[0514] 5. Confirmation of target sequence modifications

[0515] After deep sequencing (using Illumina miSeq) the cells in which the above transgene was integrated into the cell genome, we used BE-Analyzer (rgenome.net) to check whether modifications occurred within the target sequence.

[0516] The results confirming that stop codons were generated within the respective target sequences present in the gag gene and pol gene are as shown in Figures 4 and 5.

[0517] Looking at Figure 4, it can be seen that 5'-CAG-3' within the target sequence of the gag gene is modified to 5'-TAG-3'.

[0518] Looking at Figure 5, it can be seen that 5'-CAG-3' within the target sequence of the pol gene is modified to 5'-TAG-3'.

[0519] The efficiency of stop codon generation in each Colony is as shown in [Table 8] below.

[0520] Target Gene C-to-T Substitution (%) PERV- gag non-treated 0.22 Colony #1 63.15 Colony #3 52.12 PERV- pol non-treated 0.11 Colony #1 54.60 Colony #3 47.83

[0521] Through the above examples of the present application, it was confirmed that the fusion editor protein (Cas9, cytidine deaminase, UGI) included in the transgene integrated into the genome of the transfected cell, and the respective sgRNAs targeting the gag and pol genes, are expressed in the transfected cell, thereby generating stop codons within the target sequences of the gag and pol genes in the genome of the cell. Therefore, it is determined that the expression of PERV in cells transfected using the composition of the present application will be significantly suppressed. Furthermore, since the fusion protein and sgRNA targeting the aforementioned PERV gene are expected to be continuously expressed, it is expected that PERV can be continuously inactivated in the future regardless of the copy number of the PERV gene. Industrial applicability

[0522] The present application relates to a composition capable of artificially manipulating PERV genomes that exist as multiple copies within the genome of pig cells, and a method for inactivating PERV using the same.

[0524] This relates to the target sequence of the PERV gene, the gRNA sequence for targeting the PERV gene, the primer sequence, etc.

Claims

Claim 1 A method for inactivating porcine endogenous retrovirus (PERV) present in multiple copies in the genome of pigs, the method comprising the step of introducing a genetic engineering composition into pig cells; wherein the genetic engineering composition comprises: (a) a guide RNA capable of targeting a target sequence of the gag gene of PERV or a nucleic acid sequence encoding thereof; (b) a guide RNA capable of targeting a target sequence of the pol gene of PERV or a nucleic acid sequence encoding thereof; and (c) a Cas9 protein or a nucleic acid sequence encoding thereof. and (d) cytidine deaminase or a nucleic acid sequence encoding the same; wherein the target sequence is located in a continuous sequence region of 10 bp to 30 bp containing a 5'-CAG-3' sequence in the gag gene or pol gene, and the Cas9 protein is a Cas9 protein derived from Streptococcus pyogenes, and the inactivation is characterized by generating a stop codon of 5'-TAG-3' in the target sequence of the gag gene and pol gene, thereby reducing or suppressing the expression of the gag gene and pol gene of PERV and inactivating the PERV present in multiple copies. Claim 2 A method according to claim 1, wherein the target sequence of the gag gene is one of the nucleotide sequences represented by SEQ ID NOs: 132, 134, and 135, which are common sequences of each gag gene of PERV-A, PERV-B, and PERV-C subtypes, and the target sequence of the pol gene is one of the nucleotide sequences represented by SEQ ID NOs: 139 to 141, which are common sequences of each pol gene of PERV-A, PERV-B, and PERV-C subtypes. Claim 3 A method according to claim 2, wherein the guide RNA of (a) comprises one of the nucleotide sequences represented by SEQ ID NOs: 66, 68, and 69, and the guide RNA of (b) comprises one of the nucleotide sequences represented by SEQ ID NOs: 81, 85, and 87. Claim 4 A method according to claim 1, wherein the cytidine deaminese is selected from AID, PmCDA1, AICDA, ARP2, CDA2, HIGM2, APOBEC1, APOBEC2, APOBEC3A, APOBEC3B, APOBEC3C, APOBEC3D, APOBEC3E, APOBEC3F, APOBEC3G, APOBEC3H, CDA, and DCTD. Claim 5 A method according to claim 1, characterized in that the genetic engineering composition further comprises a DNA glycosylase inhibitor. Claim 6 A method according to claim 5, characterized in that the DNA glycosylase inhibitor is a uracil glycosylase inhibitor (UGI). Claim 7 A method according to claim 1, characterized in that the Cas9 protein is a Cas9 nickase (nCas9). Claim 8 A method according to claim 1, wherein the genetic engineering composition comprises a nucleic acid sequence encoding a guide RNA of (a); a nucleic acid sequence encoding a guide RNA of (b); a nucleic acid sequence encoding a Cas9 protein of (c); and a nucleic acid sequence encoding a cytidine deaminase of (d), all of which are included in a single vector, wherein the vector further comprises a nucleic acid sequence encoding a transposer or / and a transposase. Claim 9 A method according to claim 8, characterized in that the above-mentioned metabolite is a piggyBac metabolite or a Sleeping Beauty metabolite. Claim 10 delete Claim 11 A method according to claim 8, characterized in that the genetic engineering composition is integrated into the genome of the pig cell. Claim 12 A method according to claim 1, characterized in that the introduction is performed by one or more methods selected from electroporation, liposomes, plasmids, viral vectors, nanoparticles, and PTD (Protein translocation domain) fusion protein methods. Claim 13 A genetic engineering composition for inactivating porcine endogenous retrovirus (PERV), wherein the composition comprises: (a) a guide RNA or a nucleic acid sequence encoding the same, comprising one or more guide domain sequences among the nucleotide sequences represented by SEQ ID NOs: 66, 68, and 69 for targeting the gag gene of PERV; (b) a guide RNA or a nucleic acid sequence encoding the same, comprising one or more guide domain sequences among the nucleotide sequences represented by SEQ ID NOs: 81, 85, and 87 for targeting the pol gene of PERV; and (c) a Cas9 protein or a nucleic acid sequence encoding the same. and (d) cytidine deaminase or a nucleic acid sequence encoding the same; wherein the guide RNA of (a) targets all gag genes of each PERV-A, PERV-B, and PERV-C subtype, the guide RNA of (b) targets all pol genes of each PERV-A, PERV-B, and PERV-C subtype, and the Cas9 protein is a Cas9 protein derived from Streptococcus pyogenes. Claim 14 A composition according to claim 13, wherein the cytidine deaminese is selected from AID, PmCDA1, AICDA, ARP2, CDA2, HIGM2, APOBEC1, APOBEC2, APOBEC3A, APOBEC3B, APOBEC3C, APOBEC3D, APOBEC3E, APOBEC3F, APOBEC3G, APOBEC3H, CDA, and DCTD. Claim 15 In claim 13, the composition for genetic engineering is characterized by further comprising a DNA glycosylase inhibitor. Claim 16 A composition according to claim 15, characterized in that the DNA glycosylase inhibitor is a uracil glycosylase inhibitor (UGI). Claim 17 A composition according to claim 13, characterized in that the Cas9 protein is a Cas9 nickase (nCas9). Claim 18 A composition according to claim 13, wherein the guide RNA of (a) comprises one of the nucleotide sequences represented by SEQ ID NOs: 66, and the guide RNA of (b) comprises one of the nucleotide sequences represented by SEQ ID NOs:

81. Claim 19 In claim 13, the composition for genetic manipulation comprises a nucleic acid sequence encoding a guide RNA of (a); a nucleic acid sequence encoding a guide RNA of (b); a nucleic acid sequence encoding a Cas9 protein of (c); and a nucleic acid sequence encoding a cytidine deaminase of (d), all of which are included in a single vector, wherein the vector further comprises a nucleic acid sequence encoding a transposer or / and a transposase. Claim 20 A composition according to claim 19, characterized in that the above-mentioned transposer is a piggyBac transposer or a Sleeping Beauty transposer. Claim 21 delete Claim 22 delete Claim 23 delete Claim 24 delete Claim 25 A porcine endogenous retrovirus (PERV) having inactivated gag and pol genes in its genome, wherein each of the inactivated gag and pol genes contains at least two stop codons, wherein one of the at least two stop codons is a 5'-TAG-3' nucleotide sequence, wherein the inactivated PERV exists as multiple copies in the genome, wherein the inactivated PERV is a PERV-A, PERV-B, and PERV-C subtype, and wherein the expression level of the PERV is reduced by at least 50% compared to before inactivation. Claim 26 Pigs produced using the pig cells of Article 25.